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ABSTRACT 
 
The p53 family of transcription factors consists of three homologous proteins, p53, 
p63 and p73, with a central role in the control of cell differentiation, proliferation and death. 
The deregulation of this family plays a critical role in tumorigenesis and significantly affects 
tumor response to therapy. Therefore, this family is considered a key therapeutic target in 
cancer. The p53 family proteins are mainly inhibited by interaction with murine double 
minute (MDM) proteins, MDM2 and MDMX. The inhibition of these protein-protein 
interactions, for a full reactivation of p53 family proteins, represents a promising therapeutic 
anticancer strategy. Despite the vast number of inhibitors of the p53-MDM2 interaction 
already described, only few inhibitors of the p53-MDMX interaction and dual inhibitors of 
the p53-MDM2/MDMX interactions were reported to date. In addition, inhibitors of the p63 
and p73 interaction with MDM2/MDMX are still missing.   
In the present work, two new activators of the p53 and p73 pathways were 
discovered, namely an inhibitor of the p73-MDM2 interaction (the xanthone LEM2), and a 
dual inhibitor of the p53-MDM2/MDMX interactions (the phenylalaninol-derived 
oxazolopyrrolidone lactam derivative JL-1). For these findings, the yeast Saccharomyces 
cerevisiae (without orthologues of p53 family proteins) greatly contributed as a simplified 
cell-based screening assay to search for potential inhibitors of the p53 and p73 interaction 
with MDMs.  
Herein, the molecular mechanisms of action of LEM2, as an inhibitor of the p73-
MDM2 interaction, and of JL-1, as a dual inhibitor of the p53-MDM2/MDMX interactions, 
were confirmed in human tumor cell lines. Particularly, in a p53-null human tumor cell line, 
it is shown that LEM2 has a potent tumor growth inhibitory effect, higher than that obtained 
with nutlin-3a (the only known inhibitor of the p73-MDM2 interaction described to date). The 
disruption of the p73-MDM2 interaction by LEM2 was further confirmed by co-
immunoprecipitation assays. In addition, LEM2 increased the protein levels of p73 and of 
its transcriptional targets (MDM2, Bax and p21), and induced cell cycle arrest, and 
apoptosis, with PARP cleavage, ROS generation and ∆ψm dissipation. Also, LEM2 did not 
show apparent in vitro genotoxic effects. On the other hand, using human colon 
adenocarcinoma HCT116 cell lines expressing wild-type p53 (HCT116 p53+/+) and its p53-
null isogenic derivative (HCT116 p53-/-), it was shown that JL-1 exhibited a p53-dependent 
in vitro antitumor activity. In fact, JL-1 induced p53 stabilization, up-regulated p53 
transcriptional targets (MDM2, MDMX, Bax, p21, and Puma), and induced cell cycle arrest 
and apoptosis, with PARP cleavage, in p53+/+, but not in p53-/-, HCT116 cells. The disruption 
of the p53-MDM2/MDMX interactions was further supported by co-immunoprecipitation 
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assays, in HCT116 p53+/+ tumor cells.  In addition, similar tumor cytotoxic effects were 
observed for JL-1 against MDM2-overexpressing osteosarcoma SJSA-1 and MDMX-
overexpressing breast adenocarcinoma MCF-7 cell lines. JL-1 did not show apparent in 
vitro genotoxic effects and it was capable of inhibiting the migration of wt p53-expressing 
tumor cells. Importantly, JL-1 also showed promising in vivo antitumor properties against 
HCT116 p53+/+ tumor cells.  
Overall, this work provides a relevant contribution to the pharmacological knowledge 
of the p53 family proteins, with the identification of two new promising small-molecule 
activators of the p53 and p73 pathway. Besides their potential as anticancer agents, their 
scaffolds may open the way to new derivatives with improved pharmacological properties.  
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RESUMO 
 
A família da p53 é constituída por três proteínas homólogas, a p53, p63 e a p73, 
que possuem um papel fundamental no controlo da diferenciação, proliferação e morte 
celular. A desregulação desta família apresenta um papel crítico na tumorigénese e afeta 
significativamente a resposta do tumor à terapia. Desta forma, esta família é considerada 
um alvo terapêutico chave no cancro. As proteínas da família da p53 são maioritariamente 
inibidas pela interação com as proteínas murine double minute (MDM), MDM2 e MDMX. A 
inibição destas interações proteína-proteína, para uma reativação mais eficaz das 
proteínas da família da p53, representa uma estratégica terapêutica anticancerígena 
promissora. Até à presente data, apesar do número elevado de inibidores da interação p53-
MDM2 existentes, poucos são os inibidores da interação p53-MDMX e inibidores duais das 
interações p53-MDM2 e p53-MDMX descritos. Além disso, continuam por descobrir 
inibidores das interações entre p63 e p73 com as proteínas MDMs. 
No presente trabalho, foram descobertos dois novos ativadores das vias da p53 e 
da p73, nomeadamente, um inibidor da interação p73-MDM2 (a xantona LEM2), e um 
inibidor dual das interações p53-MDM2/X (uma oxazolopiperidona lactama derivada do 
fenilalaninol JL-1). Para estas descobertas, contribuiu a levedura Saccharomyces 
cerevisiae (que não possui ortólogos das proteínas da família da p53) como ensaio celular 
de screening simplificado para a pesquisa de potenciais inibidores das interações da p53 
e p73 com as MDMs.  
Neste estudo, foram também confirmados, em linhas celulares tumorais humanas, 
os mecanismos moleculares de ação do LEM2, como inibidor da interação p73-MDM2, e 
do JL-1, como inibidor dual das interações p53-MDM2/X. Em particular, em linhas celulares 
tumorais humanas que não expressam a p53, foi demonstrado que o LEM2 tem um potente 
efeito inibidor de crescimento, superior ao obtido com a nutlina-3a (o único inibidor da 
interação p73-MDM2 descrito até à data). A inibição da interação p73-MDM2 pelo LEM2 
foi confirmada por ensaios de co-imunoprecipitação. Além disso, o LEM2 promoveu o 
aumento dos níveis proteicos da p73 e dos seus alvos transcricionais (MDM2, Bax e p21), 
induziu a paragem do ciclo celular e apoptose, com clivagem de PARP, produção de 
espécies reativas do oxigénio e dissipação do potencial de membrana mitocondrial. Por 
outro lado, usando linhas celulares de adenocarcinoma do cólon HCT116, que expressam 
a forma nativa da p53 (HCT116 p53+/+) ou o seu derivado isogénico, que não expressa a 
p53 (HCT116 p53-/-), mostrou-se que o JL-1 exibiu uma atividade anti-tumoral in vitro 
dependente da p53. De facto, o JL-1 induziu a estabilização da p53, aumentou a expressão 
de alvos transcricionais da p53 (MDM2, MDMX, Bax, p21 e Puma), e induziu a paragem 
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do ciclo celular e apoptose, com clivagem de PARP, em células HCT116 p53+/+, mas não 
nas células p53-/-. A quebra das interações p53-MDM2/X foi sustentada por ensaios de co-
imunoprecipitação, em células tumorais HCT116 p53+/+. Adicionalmente, foram observados 
efeitos tumorais citotóxicos similares do JL-1 em linhas celulares de osteossarcoma SJSA-
1, que sobre-expressam MDM2, e em linhas celulares do adenocarcinoma da mama MCF-
7, que sobre-expressam MDMX. O JL-1 não apresentou aparentes efeitos genotóxicos in 
vitro e foi capaz de inibir a invasão de células tumorais que expressavam a forma nativa da 
p53. Notavelmente, o JL-1 também apresentou propriedades anti-tumorais in vivo 
promissoras em células tumorais HCT116 p53+/+. 
De uma forma geral, este trabalho representa um contributo relevante para a 
farmacologia das proteínas da família da p53, através da identificação de duas novas 
pequenas moléculas inibidoras das vias da p53 e da p73. Além do potencial como agentes 
anticancerígenos, as suas estruturas podem abrir caminho a novos derivados com 
propriedades farmacológicas melhoradas.  
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1. INTRODUCTION 
 
Cancer is one of the leading causes of morbidity and mortality worldwide, with 
approximately 14 million new cases and 8.2 million cancer-related deaths in 2012 [1]. 
According to the World Health Organization, the number of new cases will most likely 
increase about 70% over the next 20 years [1]. In fact, despite the increase in the relative 
survival rates due to improved diagnostic techniques, accuracy of prognosis and cancer 
treatments, the cancer incidence is increasing as a result of population aging and cancer-
associated lifestyles [1]. 
Tumorigenesis is a multistep process, driving the progressive transformation of 
normal cells into malignant ones. These altered cells divide and grow in the presence of 
signals that normally inhibit cell growth, and develop new functional and structural 
characteristics [2]. In fact, the malignant transformation of a cell is attributed to a variety of 
genetic and epigenetic events, involving alterations in several oncogenes and tumor 
suppressor genes. The malignant phenotype is characterized by sustained proliferation, 
evasion of growth suppressors, resistance to cell death and replicative mortality, increased 
angiogenesis, and activation of invasion and metastasis [2, 3].  
Although the complete sequence of events required for the development of human 
cancer is not completely understood, the most widely studied mechanisms are the 
inactivation of tumor suppressor genes and the activation of oncogenes. In fact, given their 
relevance for tumor initiation and progression, oncogenes and tumor suppressor genes 
have been thoroughly explored as valuable therapeutic targets [2].  
Oncogenes typically encode proteins that stimulate cell proliferation with an 
inhibition of apoptosis, and are usually activated by mutation or gene fusion, by association 
with enhancer elements, or by amplification [4]. On the other hand, tumor suppressor genes 
typically act by inhibiting cell proliferation, through suppression of cell cycle progression 
and/or apoptosis promotion. Thus, when these genes partial or totally lose their functions, 
the cell can progress to cancer, commonly in combination with other genetic alterations. In 
many tumors, these tumor suppressor genes are lost or inactivated, thereby removing 
inhibitors of cell proliferation, and contributing to the abnormal proliferation of tumor cells 
[4]. Human cells present diverse tumor suppressor genes, being the TP53, which encodes 
the p53 protein, the most studied. Mutations in this gene lead to the loss of wild-type (wt) 
p53 activity, frequently detected in many different types of cancer. On the other hand, 
perturbations in the p53 signaling pathways are believed to be required for the development 
of most cancers, and evidences suggest that the reactivation of p53 function will have 
significant therapeutic benefits (reviewed in [5]). 
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1.1. THE P53 FAMILY PROTEINS 
The p53 protein was discovered in 1979 as a nuclear protein that formed a complex 
with the SV40 tumor-virus oncoprotein, the large T-antigen [6, 7]. At this time, p53 was 
considered an oncogene. Only in 1989, p53 was established as a tumor suppressor since 
it was initially discovered as a mutant form, and wt p53 actually prevented malignant 
transformation of rat embryo fibroblasts cells by oncogenes [8]. Over the years, further 
observations demonstrated that, in fact, p53 has a tumor preventive activity. Indeed, several 
in vitro studies showed that the activity of p53 was commonly lost due to gene mutations or 
deletions in numerous cancer cell lines and tumors (reviewed in [9]). Also, the TP53 gene 
knockout mice demonstrated a high susceptibility to a variety of cancers, at a very young 
age (reviewed in [9]). Likewise, in humans, germline TP53 mutations are also associated 
with an increased cancer susceptibility and reduced age of onset, a condition called Li-
Fraumeni syndrome (reviewed in [9]). It was also shown that p53 protein acts as an 
inducible sequence-specific DNA-binding transcription factor [10], controlling the 
transcription of numerous genes involved in different cellular processes in order to prevent 
the replication of damaged DNA or the proliferation of genetically altered cells. Due to this 
fundamental role in maintenance of genomic integrity, p53 has been called “the guardian of 
the genome” [11]. 
Almost two decades after the discovery of p53, two related homologs, TP63 [12] and 
TP73 [13] (encoding p63 and p73 proteins, respectively), were described. These three 
members – p53, p63 and p73 – constitute a family of transcription factors that share a high 
level of structural similarity, wherein p63 and p73 can transactivate p53 target genes 
(reviewed in [14]). However, their functional redundancy is limited, since the primary role of 
each p53 family member, determined by transgenic knockout mice models, shows that each 
protein has its own unique roles (reviewed in [14]). For instance, p63 is critical for the correct 
development of ectodermal-derived tissues, and p63 germline mutations are associated 
with a subset of ectodermal dysplasia syndromes [15]. On the other hand, p73 is involved 
in the regulation of neural and immune systems and, to date, no syndromes associated with 
p73 germline mutations have been identified [16]. Contrary to TP53, mutations in TP63 and 
TP73 genes are rare. Still, evidences showed that both p63 and p73 exert a tumor 
suppression function in many human tumors, even though their roles are highly complex 
mainly due to the existence of several isoforms in a same cellular context [17].  
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1.1.1. STRUCTURAL FEATURES 
The TP53, TP63, and TP73 genes are located in chromosomes 17p13.1, 3q27-29, 
and 1p36.2-3, respectively [16]. The p53, p63 and p73 proteins respectively encoded by 
these genes present a high degree of structural homology, sharing three major domains: a 
transactivation domain (TAD), a DNA-binding domain (DBD), and an oligomerization 
domain (OD) (Figure 1A). The highest homology is found in the DBD (63% identity between 
p53 and p73, and 60% identity between p53 and p63) (reviewed in [16]), which explains 
why the three proteins can bind to the same DNA sequences and transactivate the same 
promoters. Regarding the OD, important for protein tetramerization, the amino acid identity 
between p53 and p63/p73 is less conserved (about 38%). This may explain why p63 and 
p73 are unable to form hetero-oligomeric complexes with wt p53 (reviewed in [16]. On the 
other hand, the OD homology between p63 and p73 is approximately 60%, what explains 
why these proteins are able to form heterotetramers, although with less efficiency than 
homotetramers [18].  
Using different promoters and/or alternative splicing, TP53, TP63 and TP73 give rise 
to multiple isoforms, some of which have completely different functions [16]. In fact, the 
proteins with an N-terminal acidic TAD, termed TA isoforms (TAp63 and TAp73), result from 
transcription initiated at the P1 promoter; the N-terminal truncated proteins lacking TAD, 
called ΔN isoforms (ΔNp63 and ΔNp73), arise from transcription initiated at the P2 promoter 
[19]. Relating to TP53, it includes a P1’ promoter that gives rise to proteins containing the 
full TAD, a P1 promoter that produces proteins lacking the first 40 amino acids residues 
(Δ40p53), and a P2 promoter whose activation gives rise to proteins lacking the first 133 
amino acids (Δ133p53) [16] (Figure 1B). The alternative splicing at the 3´end of p53, p63 
and p73 transcripts gives rise to distinct ΔN and TA isoforms: eight splice variants for p53 
(α, β, γ, δ, ε, ζ, Δp53 and ΔE6), five for p63 (α, β, γ, δ and ε), and nine for p73 (α, β, γ, δ, ε, 
θ, ζ, η and η1). Thus, it is noteworthy that the combination of alternative initiation of 
translation, alternative splicing, and alternative promoter usage can significantly increase 
protein diversity [16] (Figure 1B).  
Unlike p53, p63α and p73α isoforms possess an additional protein-protein 
interaction region at their C-terminus. It combines the sterile alpha motif (SAM), and the 
transcription inhibition domain (TID), implicated in lipid-membrane binding and repression 
of transcription through intra- or intermolecular associations with TAD (Figure 1A) [16, 17].  
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Figure 1 – Structural organization of p53 family proteins. (A) Structure of p53 family proteins. 
p53, p63 and p73 proteins consist of an amino-terminal transactivation domain (TAD), a central DNA- 
binding domain (DBD), and a carboxy-terminal oligomerization domain (OD). α-Isoforms of p63 and 
p73 encode also an additional sterile alpha motif (SAM) and a transactivation inhibitory domain (TID). 
(B) Architecture of human TP53, TP63 and TP73 genes. Transcription of p53 family genes is 
controlled by two promoters, P1 and P2. TP53 possesses an additional promoter, P1’. C-terminal 
alternative mRNA splicing leads to the generation of different isoforms of each protein. Numbered 
boxes indicate exons. C-terminal splicing events for all p53 family members are indicated by dotted 
lines and Greek letter designation (Adapted from [16]). 
 
α 
α 
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1.1.2. BIOLOGICAL FUNCTIONS  
The p53 family proteins have similar, yet non-overlapping functions. As previously 
addressed, although these proteins are quite similar in structural organization, subtle 
differences influence their ability to interact with other proteins (co-activators, co-repressors 
or other regulatory proteins), and to recognize different DNA sequences with the 
subsequent transactivation of specific target genes [20]. Therefore, the molecular flexibility 
conferred by the structural complexity among these proteins governs the functional diversity 
within the family [19].  
At physiological conditions, p53 is maintained at low levels by continuous 
ubiquitination and subsequent degradation by the proteasome [21]. However, upon 
exposure to different stress signals, including DNA damage and oncogenic stress, p53 
undergoes post-translational modifications that lead to its stabilization and activation [22]. 
Once activated, p53 accumulates in the nucleus, where it acts as a transcription factor, 
coordinating a program that eventually leads to cell cycle arrest, senescence or cell death, 
which greatly depends on the level of cellular compromise [22, 23]. However, the 
assortment of activities attributed to this protein is wider. In fact, distinct studies revealed 
that p53 is also involved in other important cellular processes, including cell metabolism, 
autophagy, DNA repair and in the antioxidant response to increased reactive oxygen 
species (ROS) levels (reviewed in [22]).  
As mentioned before, although both p63 and p73 share many functional properties 
with p53, cooperating with it in the regulation of tumorigenesis, these proteins have unique 
roles in differentiation and development of unstressed cells (reviewed in [19]). Full-length 
and truncated p63/p73 isoforms generally exhibit opposite biological functions, yet their 
activities may depend on the cellular context (reviewed in [19]). Similarly to p53, TAp63 and 
TAp73 are also tumor suppressors due to their p53-like ability to induce cell cycle arrest 
and apoptosis (Figure 2). This similarity can be explained, at least in part, by transactivation 
of an overlapping set of target genes (reviewed in [19, 24]). Indeed, although the 
identification of specific p63 and p73 targets, TAp63 and TAp73 were shown to interact with 
p53-response elements (RE) in reporter and gel-shift assays and in chromatin 
immunoprecipitation experiments (reviewed in [24]). In contrast, ΔNp63 and ΔNp73 
isoforms are potent dominant-negative inhibitors of TA isoforms and of p53, therefore acting 
as oncoproteins (reviewed in [16, 24]). It has been proposed that this ΔN transdominance 
effect can occur by two non-mutually exclusive mechanisms: i) ΔN isoforms can compete 
with TA isoforms for their target gene promoters, preventing TA-mediated transcriptional 
activity; ii) ΔN isoforms inhibit TA isoforms through formation of transcriptionally inactive 
heterocomplexes [24-26].  
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Figure 2 – Schematic representation of the biological functions of p53 family proteins. p53, 
p63 and p73 are sequence specific transcription factors. When activated by different stress 
conditions, these proteins regulate the transcription of an assortment of genes involved in different 
cellular processes with an important role in tumorigenesis such as cell cycle arrest, apoptosis, 
senescence and DNA repair. 
 
It has been shown that the ΔNp73 levels can be regulated by p53 and TAp73 through 
direct activation of the P2 promoter of p73 [25, 27, 28]. It was also demonstrated that p53 
can induce ΔNp63 expression [29]. In this way, auto-regulatory feedback loops are normally 
created in order to control the TA/ΔN ratio, and consequently, the expression levels of p53 
family target genes, which may determine cell fate [19]. Consequently, an imbalance 
between TA and ΔN isoforms may lead to tumor development [19]. Accumulating studies 
showed that patients with cancers overexpressing oncogenic ΔN isoforms present poor 
prognosis and higher chemotherapeutic failure rates (reviewed in [16]). Despite that, due to 
the existence of additional transactivation domains, ΔN isoforms may be also 
transcriptionally active [30-32], being involved in cell cycle and apoptosis regulation in a TA-
independent manner (reviewed in [24]). 
Despite the involvement of p53 family proteins in a vast number of cellular 
processes, in the present thesis, a particular attention will be given to their involvement in 
cell cycle, DNA repair and apoptosis. In fact, the primary role of p53 family proteins as tumor 
suppressors is to block cell cycle progression until DNA damage is repaired, or to induce 
apoptosis or senescence to remove irreparably damaged or malignant cells (reviewed in 
[33]).  
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Cell cycle progression control and DNA repair 
The cell cycle deregulation is a common feature of human tumor cells and results in 
unscheduled cell proliferation, associated with genomic and chromosomal instability [34]. 
As tumor suppressors, the p53 family proteins exert pivotal functions in cell cycle 
progression, since they regulate G1/S and G2/M cell cycle checkpoints [20]. 
Cell cycle consists of two consecutive periods, mainly characterized by DNA 
replication followed by its division into two separate daughter cells. Cell division occurs 
during the mitosis (M) phase, which is preceded by a preparative stage, or interphase, that 
includes Gap 1 (G1), Gap 2 (G2) and synthesis (S) phases (Figure 3). The transition 
between the cell cycle phases occurs in an orderly fashion, being regulated by different 
cellular proteins. In order to prevent the transmission of damaged genetic material to 
daughter cells, appropriate progression through each phase of cell cycle is monitored by a 
series of checkpoints (reviewed in [34]). These cell cycle checkpoints are regulated by a 
family of serine/threonine protein kinases, the cyclin-dependent kinases (Cdk), which are 
activated by direct binding to their corresponding regulatory cyclin subunits. Cdk levels are 
usually constant throughout the cell cycle, whereas cyclins levels oscillate in synchrony with 
the cell cycle. Different types of cyclins are produced during the progression through the 
various phases of the cycle. Thus, the formation of different cyclin-Cdk complexes occurs 
periodically and according to the point of cell cycle, which in turn set off different cell cycle 
events (reviewed in [34]).  
The entry into the G1 cell cycle phase is governed by the formation and activation 
of the cyclin D-Cdk4/6 complexes (Figure 3). The activation of these complexes leads to 
partial phosphorylation of retinoblastoma protein (pRb), which remains bound to the E2F 
transcription factor. During the late G1 phase, the expression of E-type cyclins leads to 
cyclin E-Cdk2 complex formation, with subsequent hyperphosphorylation of pRb and the 
E2F release. Free E2F is then able to instigate the expression of genes required for S-
phase entry. Under stress conditions, G1 arrest is induced through the inhibition of cyclin-
Cdk complexes by Cdk inhibitors, such as p21 and p57/Kip2 (reviewed in [34]) (Figure 3). 
Once activated upon different stress signals, all the three members of the p53 family induce 
the transcription of p21, which binds to cyclin D-Cdk4/6 and cyclin E-Cdk2 complexes, 
halting cell cycle progression and DNA replication, and allowing for DNA repair (reviewed 
in [20]) (Figure 3). Both TAp63 and TAp73 can also induce G1 cell cycle arrest through 
transcriptional up-regulation of p57/Kip2 [29]. p53 also promotes the up-regulation of other 
proteins that contribute to G1 arrest, namely the human cell division control protein 4b 
(hCDC4b) (Figure 3), a F-box protein and component of the Skp, Cullin, F-box (SCF) 
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ubiquitin ligase complex, that targets cyclin E for ubiquitin-mediated degradation (reviewed 
in [20]).  
 
 
Figure 3 – General representation of the cell cycle regulation by p53 family proteins. p53 family 
proteins induce cell cycle arrest by inhibiting G1/S or G2/M transition, regulating the expression of 
several proteins. CAK: cdk-activating kinase; Cdk: cyclin-dependent kinase; GADD45: growth arrest 
and DNA-damage inducible protein; Rb: retinoblastoma protein; Cdc25c: cell division cycle 25 
homolog C; hCDC4b: human cell division control protein 4b (Adapted from [20]). 
 
The G2/M checkpoint centers on the activation of the cyclin B1-Cdk1 complex 
(Figure 3). The p53 family proteins also affect this checkpoint by transcriptionally modulating 
the expression of multiple targets such as the cell division cycle 25 homolog C (Cdc25c), 
the scaffold protein 14-3-3σ, p21 and growth arrest and DNA damage inducible protein 
(GADD45) (Figure 3). Concerning to p21, although being the major mediator of G1 arrest, 
it also participates in G2 arrest through association with the cyclin B1-Cdk1 complex, 
consequently inhibiting its phosphorylation by Cdk activating kinase (CAK). In turn, 
GADD45, the first p53 target gene to be identified, associates with Cdk1, preventing its 
binding to cyclin B1 and subsequently, inhibiting its kinase activity. Both p53 and p73 induce 
the expression of 14-3-3σ, which is involved in G2 arrest by physically separating the cyclin 
B1-Cdk1 complex from its target proteins (reviewed in [20, 34]) (Figure 3). Additionally, p53 
and p73 can also induce G2/M arrest by repressing the Cdc25C, a phosphatase that 
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dephosphorylates Cdk1, leading to the cyclin B1-Cdk1 complex activation (Figure 3). It has 
also been reported that the proteins MCG10 (a RNA-binding protein), Reprimo (a highly 
glycosylated protein that is thought to play a role in cyclin B1-Cdk1 localization) and B99 (a 
protein with microtubule localization) are involved in G2 arrest, and their expression is 
induced by p53 (reviewed in [20, 22]) (Figure 3).  
 
In addition to their multi-faceted roles in cell cycle, p53 family proteins are also 
engaged in DNA repair mechanisms, contributing to the maintenance of genomic integrity. 
Eukaryotic cells have several pathways for DNA repair that use unique enzymatic 
machinery, which is activated depending on the type of DNA damage [35]. In fact, the p53 
family proteins can physically interact with or transcriptionally induce different DNA repair 
proteins. As referred above, these proteins can induce the expression of GADD45, which 
besides its functions in cell cycle arrest, is also involved in the nucleotide excision repair 
(NER) mechanism. p53 also interacts with several other factors that play a role in NER, 
namely transcription factor II human (TFIH, one of several general transcription factors that 
make up the RNA polymerase II pre-initiation complex) and the helicases XPB and XPD. 
p53 has been shown to interact with DNA polymerase β to stabilize the interaction between 
damaged DNA and base excision repair (BER) machinery [20, 22]. 
The intervention of p53 family proteins in DNA repair is a more complex process. 
However, herein, it was only intended to provide a brief overview about this issue, since it 
is not the focus of this thesis.  
 
 
Apoptosis induction  
Apoptosis is the most important form of cell death in multicellular organisms, given 
its significance in the control of cell proliferation and tissue homeostasis maintenance, as 
well as in the elimination of harmful or unnecessary cells [36]. This highly complex process 
is triggered by either internal or external signals, without boosting an immune system 
response and consequently, occurring without an associated inflammatory process [37]. 
Apoptotic cells present typical morphological alterations that include cell shrinkage, nuclear 
condensation and fragmentation, dynamic membrane blebbing, and loss of adhesion to 
extracellular matrices or to neighboring cells. Biochemical alterations include chromosomal 
DNA cleavage into internucleosomal fragments, phosphatidylserine externalization, and 
activation of a family of proteases, called caspases that cleave essential cellular 
components, leading to proteolytic dismantling of the cell (reviewed in [36, 38]). An aberrant 
function of any of the regulatory molecules involved in apoptosis, largely contributes to 
different pathological disorders, such as cancer. In fact, the evasion of apoptosis is a well-
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established hallmark of this disease [3]. Therefore, the intensive study of apoptotic 
mechanisms, as well as of its interveners has enabled the development of effective drugs 
that, targeting specific apoptotic pathways or proteins, increase the sensitivity of cancer 
cells to apoptotic stimuli [36]. Because p53 family proteins act as stressor sensors and 
tumor suppressors, it is not surprising that these proteins have a role in apoptosis induction. 
In fact, the understanding of the mechanism of apoptosis regulation by p53 family proteins 
represents an excellent opportunity to discover new anti-cancer therapies. 
In mammals, there are two pathways by which a cell can initiate apoptosis: the 
extrinsic (or death receptor-mediated pathway) and the intrinsic (or mitochondria-mediated 
pathway) (reviewed in [36, 37]) (Figure 4). Mechanistically, the p53 family can induce 
apoptosis by transcriptional activation of critical regulators of both pathways (reviewed in 
[20]) (Figure 4). However, in case of p53, it can also induce apoptosis by directly interacting 
with specific proteins, influencing mitochondrial membrane physiology (reviewed in [22]). In 
order to understand the involvement of the p53 family in apoptosis, it is required to have a 
detailed knowledge of both pathways.  
 
 
Figure 4 - Regulation of intrinsic and extrinsic apoptotic pathways by p53. p53 induces the 
expression of proteins involved in intrinsic and extrinsic apoptotic pathways. In the extrinsic pathway, 
the binding of ligands to specific trans-membrane death receptors leads to the recruitment of the 
adaptor molecule, FADD. Then, the procaspase-8 binds to FADD leading to DISC formation and 
resulting in caspase-8 activation. Activated caspase-8 directly activates executioner caspases-3, -6, 
and -7, or cleaves the pro-apoptotic protein Bid. The intrinsic/mitochondrial pathway involves several 
interactions between different anti- and pro-apoptotic members of the Bcl-2 family in order to induce 
MOMP and cyt c release. p53 induces the expression of proteins, such as Puma and Noxa, which 
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bind to and inhibit the activity of the anti-apoptotic proteins Bcl-2/Bcl-xL, allowing the translocation of 
cytosolic Bax to the mitochondria. This leads to mitochondrial permeabilization and to the release of 
cyt c from the mitochondria to the cytosol, resulting in the formation of the apoptosome and caspase-
9 activation. The activation of executioner caspases leads to cell death. The green star markers refer 
to p53 transcriptional targets. Apaf-1: apoptotic protease activating factor 1; Bax: Bcl-2 associated X 
protein; Bid: BH3 (Bcl-2 homology domain 3) interacting domain death agonist; FADD: Fas-
associated protein with death domain; p53AIP: p53-regulated apoptosis inducing protein 1; Puma: 
p53-upregulated modulator of apoptosis (Adapted from [36]). 
 
The extrinsic pathway begins with the attachment of extracellular ligands, such as 
tumor necrosis factor (TNF), Fas ligand (Fas-L), and TNF-related apoptosis-inducing ligand 
(TRAIL), to cell surface death receptors like the type 1 TNF receptor, Fas (also called 
CD95/Apo-1), and TRAIL receptors DR4 and DR5 (reviewed in [36, 37]) (Figure 4). The 
activation of these receptors leads to their trimerization and clustering of their intracellular 
death domain region, which binds to the corresponding protein motif of adaptor proteins 
such as Fas-associated death domain (FADD) and TNF receptor-associated death domain 
(TRADD). These adaptor proteins present other interaction domain, called the death 
effector domain (DED), that interacts with the DED of pro-caspase-8. This binding leads to 
the formation of the death-inducing signaling complex (DISC), and consequently to pro-
caspase-8 activation. In turn, depending on the cell type, active caspase-8 activates the 
executioner pro-caspases-3, -6 and -7, leading to cell death by damage or destruction of 
important cellular structures, or promotes the generation of a mitochondria-permeabilizing 
fragment, called the truncated Bid (tBid) (reviewed in [36, 39]) (Figure 4). Death receptor-
mediated apoptosis can be inhibited by a protein called c-FLIP, which will bind to FADD and 
caspase-8, rendering them ineffective [40, 41]). 
The intrinsic pathway can be activated by different stimuli that are sensed by several 
intracellular proteins that transmit signals to mitochondria, leading to mitochondrial outer 
membrane permeabilization (MOMP), loss of mitochondrial transmembrane potential 
(Δψm), and to the release of pro-apoptotic proteins such as cytochrome c (cyt c), apoptosis-
inducing factor (AIF), endonuclease G (EndoG), second mitochondria-derived activator of 
caspase/direct IAP-binding protein with low isoelectric point (Smac/DIABLO), and serine 
protease high-temperature requirement protein A2 (Omi/HtrA2) (reviewed in [37]) (Figure 
4). Once released from mitochondria, cyt c interacts with the apoptosis protease-activating 
factor (Apaf-1) and pro-caspase-9, forming the apoptosome. The apoptosome formation 
leads to pro-caspase-9 activation that, in turn, activates pro-caspases-3, -6 and -7, 
triggering apoptosis (reviewed in [37, 38]) (Figure 4). Smac/DIABLO [42] and Omi/HtrA2 
[43] were reported to promote apoptosis by inhibiting the activity of different inhibitors of 
apoptosis proteins (IAP) (Figure 4). On the contrary, AIF and EndoG can translocate to the 
nucleus, promoting cell death in a caspase-independent manner, through induction of 
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chromatin condensation and cleavage of nuclear DNA (reviewed in [36]). The regulation of 
this apoptotic pathway is mainly controlled by distinct proteins of the Bcl-2 family, whose 
main function is thought to be the regulation of cyt c release from mitochondria to the 
cytosol, via alteration of the mitochondrial membrane permeability (reviewed in [44]). This 
family is composed by pro-apoptotic (e.g., Bax, Bak, Bad, Puma, Noxa, Bid and Bim) and 
anti-apoptotic (e.g., Bcl-xL and Bcl-2) members (reviewed in [36]). Anti-apoptotic proteins, 
like Bcl-2 and Bcl-xL, may interact with mitochondrial proteins involved in mitochondrial 
pores formation, thereby protecting the mitochondrial membrane integrity, and inhibiting the 
release of cyt c (reviewed in [44]). On the other hand, the activation of the pro-apoptotic 
protein Bax leads to its translocation from the cytosol to the outer mitochondrial membrane, 
where it can homodimerize or heterodimerize with Bak or tBid, leading to the disruption of 
the mitochondrial membrane integrity and potentiating the release of cyt c [45] (Figure 4). 
Other pro-apoptotic proteins, as Puma and Noxa, exert their pro-apoptotic effects by binding 
to the anti-apoptotic proteins, blocking their activity (reviewed in [36, 39]). Also, the p53-
apoptosis inducing protein 1 (p53AIP1) localizes to mitochondria, where it interacts with Bcl-
2 protein, leading to the release of cyt c and to the consequent apoptosis induction [46]. 
Therefore, the ratio between pro-apoptotic and anti-apoptotic proteins dictates whether or 
not cells are committed to die (reviewed in [37, 39]).  
 Regarding to the regulation of the extrinsic pathway by p53 family proteins, p53, 
TAp73 and TAp63 were shown to up-regulate the expression of the cell death receptor 
Fas/CD95 [47-49]. TRAIL receptors, DR4 and DR5 [50-52], and caspase-8 [53] have been 
described as p53 transcriptional targets. TAp63 was shown to induce the expression of 
DR4, DR5 and TNF-R1 [48] and caspase-8, as well to regulate c-FLIP expression [54]. 
Concerning to the intrinsic pathway, the p53 family proteins upregulate pro-apoptotic 
proteins of the Bcl-2 family, namely Bax and Puma [55-57]. Both p53 and p73 induce the 
expression of Noxa and p53AIP1, with consequent apoptosis induction [46, 58, 59]. p53 
was shown to repress the expression of the anti-apoptotic proteins Bcl-2 and Bcl-xL [60], 
and to up-regulate Apaf-1, caspase-6 and Bid [61-63]. The mitochondrial chloride 
intracellular channel (mtCLIC/CLIC4), an organellular chloride channel protein that reduces 
Δψm, was also shown to be transcriptionally regulated by p53 [64]. 
 Besides its transcriptional function, evidences showed that p53 itself may localize to 
mitochondria, where it can form a complex with Bcl-xL and Bcl-2, leading to MOMP 
induction and cyt c release (reviewed in [65]). Also, cytosolic p53 can activate Bax and Bak 
through direct protein-protein interaction (reviewed in [66]). Similarly to p53, p73 also has 
transcription-independent pro-apoptotic functions [67]. In fact, it was demonstrated that the 
transcription-deficient p73 mutant p73R293H (corresponding to the hotspot mutant 
p53R273H) can still efficiently induce apoptosis in response to TRAIL, by a mechanism that 
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involves localization of p73 to mitochondria and interaction with mitochondrial p53 [68]. 
Remarkably, it was shown that p73 is targeted by caspases during apoptosis, and caspase-
cleaved p73 fragments localize to mitochondria to up-regulate apoptosis [67]. 
 
ROS are generated as products of normal mitochondrial function, and increased 
ROS levels are caused by oxidative stress. The production of ROS has been associated 
with p53-induced apoptosis, since several authors showed an increase of the cellular ROS 
levels upon p53 overexpression (reviewed in [20]). The p53 family proteins commonly 
regulate a variety of proteins that participate in ROS-mediated apoptosis, such as ferrodoxin 
reductase and REDD1/HIF-1 (reviewed in [20]). On the other hand, p53 was shown to 
transactivate p53 inducible genes (PIGs) 3 and 6, which encode redox proteins and are 
implicated in ROS generation (reviewed in [69]). Other candidates were added to the list of 
p53-induced pro-oxidant genes, namely BAX, PUMA, and p66Shc. Additionally, p53 was 
shown to be involved in the suppression of antioxidant proteins, leading to increased cellular 
ROS production, namely manganese superoxide dismutase (MnSOD), PIG12, and 
aldehyde dehydrogenase (ALDH) 4 (reviewed in [69]). 
 
 
1.2. ENDOGENOUS MODULATORS OF P53 FAMILY PROTEINS 
 The cellular processes in which the p53 family is involved are tightly regulated in 
order to maintain normal tissue homeostasis. Although the ability of p53, p63 and p73 to 
respond to cellular stress is necessary to prevent tumor growth, the deregulation of their 
cellular levels can lead to quite drastic cell death-dependent effects. In particular, excessive 
cell death can compromise the structure and function of tissues, which is a hallmark of 
aging, whereas deficient cell death can lead to neoplastic disorders [70].  
The p53 family proteins are mainly regulated at post-translational level by several 
proteins, undergoing modifications (e.g. phosphorylation, acetylation and ubiquitination), 
which control their turnover and activity [17]. The two major negative modulators of p53 
family proteins are the homologs murine double minute 2 (MDM2) and murine double 
minute X (MDMX, also known as MDM4) proteins (reviewed in [71]). In normal cells, MDM2 
and MDMX suppress the activity of p53 family proteins. However, under stress conditions, 
an inhibition of MDMs allows that p53, p63 and p73 may respond to the damages (reviewed 
in [17, 71, 72]). As inhibitors of the p53 family activities, MDM2 and MDMX are oncogenic 
when overexpressed, exhibiting important roles in tumorigenesis and tumor progression 
[72]. In fact, the amplification or up-regulation of MDM genes is frequently found in many 
human tumors (reviewed in [73]). 
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1.2.1. MDM2 AND MDMX: PROTEIN STRUCTURE 
MDM2 was discovered as one of the genes amplified on double minute 
chromosomes in transformed mouse NIH3T3 fibroblasts [74]. Later studies revealed that 
MDM2 was able to bind to p53, inhibiting its transcriptional activity [75, 76]. MDMX was later 
identified, through screening of a mouse cDNA expression library, as a novel protein able 
to interact with p53 [77]. The authors also demonstrated that like MDM2, MDMX co-
immunoprecipitated with p53, and its overexpression inhibited the p53 transcriptional 
activity [77].  
Human MDM2 and MDMX are proteins of 491 and 490 amino acids, respectively 
that share a high degree of structural similarity (Figure 5). Both proteins present a 
homologous p53-binding domain at the N-terminal that mediates their interaction with the 
p53 TAD and the inhibition of the p53 transcriptional activity (reviewed in [78]). Another well-
conserved region is the RING-finger domain, located at C-terminal end of both proteins. 
Concerning to MDM2, this domain is important for homo-dimerization and hetero-
dimerization with MDMX, via RING-RING interaction. Along with the zinc-finger and acidic 
domains, the RING-finger domain is essential for the MDM2 function as an E3 ubiquitin 
ligase (reviewed in [78]). The major difference between MDM proteins is that, contrary to 
MDMX, MDM2 has both nuclear localization and export sequences, which allow it to shuttle 
between the cytoplasm and the nucleus. The lack of such sequences indicates that MDMX 
is primarily localized in the cytoplasm and depends on other proteins, such as MDM2, for 
nuclear localization (reviewed in [72, 79]) (Figure 5).  
 
 
Figure 5 – Schematic representation of MDM2 and MDMX domains. Both MDM2 and MDMX 
proteins comprises a p53-binding domain, an acidic and a zinc-finger domain in their central portion 
followed by a C-terminal RING-finger domain. Additionally, the MDM2 protein possesses a nuclear 
localization signal (NLS) and a nuclear export signal (NES) sequence (Adapted from [80]). 
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1.2.2. P53 FAMILY-RELATED BIOLOGICAL FUNCTIONS OF MDMS 
Genetic studies have shown that both MDM2 and MDMX are two essential p53 
negative regulators, since the absence of MDMX or MDM2 expression leads to mice 
embryonic lethality, which was rescued by the concomitant deletion of TP53 [81]. These 
studies also demonstrated that, despite their high homology, neither MDM2 nor MDMX can 
compensate for one another in vivo to inhibit p53, showing that both MDMs have non-
redundant roles (reviewed in [82]).  
Regarding the regulation of p53 by MDM2, both proteins form an autoregulatory 
feedback loop [83, 84]. Once activated, p53 binds to the P2 promoter of MDM2 inducing its 
transcription. In turn, MDM2 binds to the N-terminal of p53, via its N-terminal hydrophobic 
region [85], and negatively regulates the p53 by three different mechanisms: i) MDM2 binds 
to the p53 TAD, thereby preventing its interactions with the basal transcription machinery 
and transcriptional co-activators, such as p300; ii) MDM2 induces p53 translocation from 
the nucleus to the cytoplasm, through its nuclear export signal domain, where p53 can no 
longer act as a transcription factor; iii) MDM2 functions as an E3 ubiquitin ligase leading to 
p53 ubiquitination and targeting it to degradation (reviewed in [86, 87]) (Figure 6). In fact, 
high levels of MDM2 favor the p53 poliubiquitination, leading to its proteasomal degradation. 
Therefore, this process is responsible for the maintenance of low levels of p53 in unstressed 
cells. On the other hand, the MDM2 RING-finger domain-mediated ubiquitination has also 
been shown to cause changes in p53 localization (reviewed in [88]). Low MDM2 levels favor 
monoubiquitination of p53, promoting its nuclear export and preventing its transcriptional 
activity. In addition, it can also trigger cytoplasmic p53 translocation to mitochondria, where 
it is deubiquitinated, causing a transcription-independent induction of apoptosis (reviewed 
in [72, 82, 88]).  
Similarly to MDM2, MDMX binds to the p53 TAD, inhibiting its transcriptional activity 
(reviewed in [77, 85]) (Figure 6). MDMX does not possess E3 ligase activity itself, however 
Lyappan et al (2010) showed that MDMX can be modified within its RING- and zinc-finger 
domains, giving to this protein a minimal E3 ubiquitin ligase activity [89]. Also, unlike MDM2, 
MDMX does not induce p53 nuclear export and degradation (reviewed in [72, 73]). More 
recently, studies showed that MDMX is also involved in the p53 stability and promotes the 
p53 mitochondrial apoptosis (reviewed in [90, 91]). In fact, under different forms of DNA 
damage, MDMX can be phosphorylated by protein kinases, and degraded by MDM2, or it 
can be phosphorylated and exported out of the nucleus, leading in both cases to p53 
activation. It was also demonstrated that a fraction of MDMX can be located at mitochondria, 
where it promotes the mitochondrial localization of phosphorylated p53 and its binding to 
Bcl-2, with consequent cyt c release and apoptosis (reviewed in [91, 92]). 
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Still, several evidences point out to an intricate network between MDM2 and MDMX 
in p53 regulation [82, 93]. Some studies have predicted that the formation of MDMX-MDM2 
heterodimers is structurally favored over the formation of homodimers of either protein. It 
has been shown that MDMX-MDM2 complexes stabilize MDM2 and enhance the ability of 
MDM2 to ubiquitinate p53 (Figure 6). In the meantime, disruption of the MDMX-MDM2 
complex resulted in p53 activation in vivo (reviewed in [82]).  
 
 
Figure 6 – Regulation of p53 by its endogenous negative modulators MDM2 and MDMX. Both 
MDM2 and MDMX bind to p53, modulating its transcriptional activity by preventing its interaction with 
the general transcription machinery. As a homodimer, MDM2 promotes p53 nuclear export to the 
cytoplasm for ubiquitin-mediated degradation by the proteasome. Additionally, MDM2 can form a 
heterodimeric complex with MDMX, promoting the degradation of p53 (polyubiquitination). Ub: 
ubiquitin (Adapted from [94]). 
 
Given the considerable structural homology between the p53 family members, it is 
plausible that MDMs may also regulate p63 and p73 activities in a similar manner to that 
described for p53. The ability of MDM2 and MDMX to bind to p73 has been well 
documented, but the results obtained for the interaction of MDMs with p63 have been 
controversial (reviewed in [95]). According to Zdzalik et al (2010), the affinities of MDM2 
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and MDMX for p73 are of the same order of magnitude as those for p53 [96]. The same 
study also showed that both p63 and p73 interact more strongly with MDMX, suggesting 
that MDMX may have a stronger impact than MDM2 on the p63 and p73 regulation [96]. 
This study also supported the interaction between MDMs and p73, as previously suggested 
by other studies (reviewed in [95]). In fact, regarding to p73, MDMs were shown to bind to 
the p73 TAD, inhibiting its transcriptional activity. However, unlike what occurs with p53, 
MDM2 does not promote p73 ubiquitination [97-99]. Instead, MDM2 relocalizes p73 to 
subnuclear speckles, preventing its interaction with the acetyltransferase p300/CBP and 
RNA polymerase-associated factor and consequently, repressing the p73 transcriptional 
activity [98, 100]. Remarkably, MDM2 can also catalyze the addition of the small ubiquitin-
like protein NEDD8 to p73, which seems to inhibit their transcriptional activity [101]. 
Contrariwise, Zdzalik et al (2010) also showed that the interactions between MDMs 
and p63 are weaker, which may explain the contradictory results reported by several groups 
[96]. In fact, by co-immunoprecipitation analysis, some groups reported the absence of 
interaction between p63 and MDM2/MDMX, in human tumor cells, as well as the absence 
of effect of both MDM proteins on p63 stability and transcriptional activity [99, 102]. 
Conversely, other studies were able to detect MDM-p63 complexes, although reporting 
contradictory effects on p63 function [103, 104]. In fact, Kadakia et al (2001), showed that 
the interaction between p63 and MDMs leads to the downregulation of the p63 
transcriptional activity [103]. These authors also showed that MDM2, but not MDMX, 
induced p63 nuclear export, inhibiting the p63-dependent apoptosis. In turn, Calabró et al 
(2002) reported that MDM2 binds to p63, leading to an increase of its transcriptional activity 
[104]. In 2010, it was reported that MDM2 was also able to interact with ΔNp63, which lacks 
the TAD involved in the interaction with MDM2 [105]. In this work, it was also demonstrated 
that this interaction promotes the ΔNp63 nuclear export, but not its degradation. 
More recently, Stindt et al (2014) showed that MDM2 co-immunoprecipitated with 
both TAp73 and ΔNp73, and to a much lesser extent with TAp63 and ΔNp63. These 
differences reflected a stronger inhibition of TAp73 and ΔNp73 transcriptional activity by 
MDM2 when compared to that observed on TAp63 and ΔNp63 [106]. 
 
 
1.3. THE P53 FAMILY IN CANCER TARGETED THERAPY 
Currently, around 22 million people with cancer present defects in p53 signaling 
(reviewed in [107]). Approximately 50% of these cases are tumors with mutations in the 
TP53 gene, which prevent the proper folding of the p53 protein or directly disrupt its binding 
to target genes as a functional tetramer. The remaining tumors retain a wt p53 form that 
 20 
 
remains inactive due to enhanced degradation or inhibition, frequently caused by 
overexpression of the negative regulators MDM2 and MDMX, through gene amplification or 
mutation (reviewed in [82]). Given the critical roles in cancer pathogenesis, particularly in 
therapy resistance, the reactivation of the p53 function is a promising anti-cancer 
therapeutic strategy [22].  
In tumors retaining the wt p53 inactivated by MDMs, the pharmacological strategies 
to activate p53 include the: i) repression of MDM2 and MDMX expression; ii) inhibition of 
the MDM2 E3 ubiquitin ligase activity; and iii) inhibition of the p53-MDM2/MDMX 
interactions (reviewed in [73, 108]).  
High levels of MDM2 are commonly found in human cancers, including sarcomas, 
gliomas, hematologic malignancies, melanomas and carcinomas, while gene amplification 
and consequent upregulation of MDMX was found in tumors, such as gliomas, soft tissue 
sarcoma, head and neck squamous carcinoma, retinoblastoma, melanoma, and breast 
cancer (reviewed in [71]). A possible strategy to reduce the expression of MDM proteins in 
cancer cells is to specifically target them with interfering RNA (RNAi), despite the delivery 
and cellular uptake limitations related to this kind of therapy (reviewed in [73]). To date, two 
small molecules that downregulate MDMX levels, causing a p53-dependent transactivation 
of pro-apoptotic genes in several cancer cell lines, were identified: the benzofuroxan 
derivative XI-006 (NSC207895) [109], and the pseudourea derivative XI-011 (NSC146109) 
[110].  
Regarding the development of small molecules that inhibit the MDM2 ubiquitin ligase 
activity, it was shown that HLI98, a member of the pyrimido-dione-quinoline family, could 
bind to the MDM2 C-terminal, compromising its function, suppressing p53 degradation, and 
leading to a p53-dependent apoptosis in tumor cells [111]. Later, a more soluble derivative 
was identified, HLI373, with higher in vitro potency, although in vivo studies are still required 
[112]. Other authors identified the small molecule JNJ-26854165 that reactivates p53 by 
inhibiting MDM2 E3 ubiquitin ligase, and inhibits tumor growth in mouse xenograft models. 
JNJ-26854165 entered phase I clinical trials (reviewed in [71]). Additionally, two natural 
products that inhibit the MDM2 E3 ubiquitin ligase activity, the Lissoclinidine B [113] and 
Sempervirine [114], have been also identified. 
Among the different strategies to restore the p53 function in tumor cells, the most 
exhaustive research has been focused on the identification of small molecule inhibitors of 
the p53-MDM2/MDMX interactions. Targeting protein-protein interactions by small 
molecules is a challenging task, since it usually involves large and flat surfaces that are 
difficult to disturb by low molecular weight compounds [86, 107]. However, the knowledge 
about protein-protein interaction architecture provides a framework to design small 
molecules that mimic one of the proteins involved in that interaction [86]. 
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In the case of the p53-MDM2 interaction, structural studies revealed that there is a 
hydrophobic cleft on MDM2 for p53 binding and only just three amino acid residues of p53 
(Phe19, Trp23, and Leu26) are crucial for the interaction (reviewed in [107, 108, 115]). 
Based on this, during the last years, a huge number of small molecule inhibitors of the p53-
MDM2 interaction, belonging to different chemical families, such as sulphonamides, 
quiloninoles, terphenyls, cis-imidazolines, benzodiazepinediones, spiro-oxindoles, 
pyrrolidine-2-ones and isoindolinones, has been described (reviewed in [115]).  
The first potent and selective small molecule inhibitors of the p53-MDM2 interaction, 
named nutlins, were identified by Vassilev et al in 2004. This group showed that this class 
of cis-imidazoline compounds were able to displace p53 from its complex with MDM2 [116]. 
Nutlins mimick the three critical amino acid residues of p53 and interact with MDM2 at the 
p53 binding site (reviewed in [117]). In vitro, nutlin-3a promoted p53 accumulation and 
activation, triggering the transcription of p53 target genes, cell cycle arrest in G1 and G2 
phases, and apoptosis [116]. As expected, nultin-3a exhibited tumor suppression activity in 
cell lines with functional p53 rather than in cell lines with mutant or deleted p53 [116]. 
However, the modest in vivo activity of nutlin-3a encouraged its optimization, leading to 
RG7112, with higher potency and improved pharmacological properties [118]. This 
compound has already entered phase I clinical trial for the treatment of solid tumors, 
hematologic neoplasms and leukemia (reviewed in [73]). 
A structure-based screening of compounds, combined with molecular modeling, led 
to the identification of spiro-oxindole-based molecules as p53-MDM2 interaction inhibitors 
[119]. MI-219 is highly specific, with subnanomolar affinity to MDM2, good pharmacokinetic 
and pharmacodynamic properties. This compound has been shown to increase the levels 
of p53 and p53-target genes, such as cyclin-dependent kinase inhibitor 1A (CDKN1A, which 
encodes p21) and MDM2, inducing cell cycle arrest and apoptosis [120]. 
On the contrary, the furan derivative RITA (reactivation of p53 and induction of tumor 
cell apoptosis) has been proposed to inhibit the p53-MDM2 interaction, both in vitro and in 
vivo, by binding to the N-terminal domain of p53, instead of MDM2, inducing p53 
accumulation and p53-dependent growth arrest and apoptosis in carcinoma cell lines [121]. 
However, NMR structural studies performed by Krajewski et al (2005) indicated that this 
compound did not directly target p53, suggesting that RITA can selectively target cells 
expressing p53 by other mechanisms, namely by interaction with other binding proteins and 
co-factors, or by stabilization of the complex against ubiquitin-driven proteolysis [122]. 
Therefore, more details are still required to better understand the molecular mechanism of 
action of RITA. 
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Given the considerable number of compounds described as inhibitors of the p53-
MDM2 interaction, Table 1 covers the existing p53-MDM2 interaction inhibitors currently in 
clinical trials.  
 
Table 1 – Small molecule inhibitors of the p53-MDM2 interaction currently in clinical trials (Adapted 
from [108]). 
Compound Study phase 
ClinicalTrials.gov 
identifiers 
RG7112 (also known as 
RO5045337) 
Phase I trial in advanced solid tumors, 
solid tumors, haematological neoplasms 
and liposarcomas (all completed) 
NCT00559533 
NCT01164033 
NCT00623870 
NCT01143740 
RG7112 with cytarabine Phase I in AML (completed) NCT01635296 
RG7112 with doxorubicin 
Phase I in soft tissue sarcoma 
(completed) NCT01605526 
RO5503781 
Phase I in advanced malignancies 
(recruiting) NCT01462175 
RO5503781 with cytarabine Phase I in AML (recruiting) NCT01773408 
MI-773 (also known as 
SAR405838) 
Phase I in malignant neoplasms 
(recruiting) NCT01636479 
DS-3032b 
Phase I in advanced solid tumor 
lymphoma (recruiting) NCT01877382 
CGM097 Phase I in advanced solid tumors NCT01760525 
AML – Acute myeloid leukaemia 
 
 
Concerning to the p53-MDMX interaction, to date, a very low number of inhibitors 
have been identified. The p53-binding pockets of MDMX and MDM2 are structurally 
different, which justifies that MDM2 inhibitors, such as nutlins, have low affinity for the p53-
binding pocket of MDMX (reviewed in [108]). Through X-ray crystallographic studies, 
Popowicz et al (2010) reported the first inhibitor of the p53-MDMX interaction, the small 
molecule WK298, which binds to MDMX in the p53 binding pocket [123]. However, the 
biological effects of this compound in tumor cells remain unavailable. Additionally, through 
a high-throughput screening of chemical libraries, SJ-172550 was identified as a lead 
compound that disrupts the p53-MDMX interaction [124]. This compound forms a reversible 
covalent complex with MDMX, and induces p53-dependent cytotoxic effects in MDMX-
overexpressing tumor cells [124]. 
Since both MDMs interact with p53, negatively regulating its activity, the 
simultaneous inhibition of the p53-MDM2/MDMX interactions, for a full p53 reactivation, has 
emerged as a promising therapeutic strategy [82]. However, few small molecules with that 
function were identified so far. The pyrrolopyrimidine-based compound 3a was identified as 
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a dual inhibitor of the p53-MDM2/MDMX interactions, leading to the increase of p53 and 
p21 expression levels and to apoptosis in a p53-dependent manner [125]. The indolyl 
hydantoin RO-5963, an optimization of RO-2443, binds to the p53-binding pocket of MDM2 
and MDMX by inducing the formation of dimeric protein complexes [126]. It has a potent 
inhibitory activity in vitro, leading to a p53-dependent cell cycle arrest and apoptosis in 
MDMX-overexpressing tumor cells [126]. Although nearly equipotent in vitro, RO-5963 was 
more effective in disrupting the p53-MDMX interaction than the p53-MDM2 interaction [126]. 
By fluorescence polarization (FP) and isothermal titration calorimetry (ITC) assays, Qin et 
al (2014) identified the cis-imidazoline derivative H109 as a dual small molecule inhibitor of 
MDM2/MDMX [127]. This compound can reactivate the p53 pathway in several cancer cell 
lines [127]. More recently, the (S)-tryptophanol derivative OXAZ-1 was identified from the 
screening of a small library of enantiopure tryptophanol-derived oxazolopiperidone lactams 
as a dual inhibitor of the p53-MDM2/MDMX interactions [128]. It was reported to induce a 
p53-dependent in vitro tumor growth-inhibitory effect, with p53 stabilization and subsequent 
up-regulation of p53 transcription targets, such as p21, Puma and Bax, and to trigger a p53-
dependent mitochondria-mediated apoptosis [128].  
As previously referred, both TP63 and TP73 are rarely mutated in human cancers, 
thus an appropriate regulation of the p63 and p73 pathways represents an important 
anticancer therapeutic challenge, particularly in p53-null or mutant p53-expressing tumor 
cells [17, 129]. In fact, all p53 family proteins function as molecular hubs of a highly 
interconnected signaling network. Thus, not only the p53 pathway, but the entire p53 family 
pathway is a primary target for anti-cancer drug development. Particularly, the activation of 
pro-apoptotic isoforms of p63 and p73 represents an undeniable promising anticancer 
strategy [129]. 
Regarding p73, the proper stimulation of TAp73 expression and function in cancer 
cells represents an appealing anticancer pharmacological approach. Different 
chemotherapeutic compounds are able to achieve this goal by different ways, including the: 
i) stimulation of TP73 transcription or inhibition of p73 degradation, leading to increased 
TAp73 levels; ii) modulation of the expression or function of TAp73 upstream regulators; 
and iii) displacement of p73 from inhibitory interactions with other cellular proteins, namely 
MDM2, MDMX, ΔNp73 and mutant p53 (reviewed in [129]). Nevertheless, considering the 
scope of this thesis, only the therapeutic strategies involving the disruption of the p73-
MDM2 interaction will be discussed. Besides blocking the p53-MDM2 interaction in wt p53-
expressing cells, some studies showed that nultin-3a was also able to exert a tumor growth 
inhibitory effect and to induce apoptosis in p53-null [130, 131] or mutant p53-expressing 
human tumor cells [132]. This p53-independent effect of nultin-3a was attributed to a 
possible p73 activation, through inhibition of its interaction with MDM2. In fact, since both 
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p53 and p73 bind to the same MDM2 hydrophobic pocket [97], it was predicted that nutlin-
3a could prevent the formation of p73-MDM2 complexes. Indeed, Lau et al (2008) confirmed 
that nultin-3a effectively displaces TAp73α from MDM2, in p53-null human colon 
adenocarcinoma cell line, leading to the increase of the p73 transcriptional activity with up-
regulation of p73 targets, such as Noxa, Puma and p21, and to enhanced apoptosis [131]. 
Moreover, nutlin-3a increases doxorubicin-mediated cell death, in a p53-null neuroblastoma 
cell line LA155N, by the combined up-regulation of TAp73 and activation of the E2F1 
transcription factor [130]. Based on these results, it was postulated that nutlin-3a acts by 
releasing the E2F1/p73 complex from the inhibitory MDM2 binding, while doxorubicin-
mediated DNA damage promotes phosphorylation of E2F1 by Chk1/Chk2 kinases, thus 
stabilizing E2F1 and promoting E2F1-mediated TAp73 transcription and activation [130].  
Concerning to p63, to date, no small molecule inhibitors of its interaction with MDMs 
have been described (reviewed in [133]). 
 
 
1.4. YEAST AS A CELL MODEL TO STUDY P53 FAMILY PROTEINS 
The yeast Saccharomyces cerevisiae has long been used as a valuable eukaryotic 
model. Actually, this cell system has greatly contributed to the elucidation of the molecular 
mechanisms underlying several human diseases, such as cancer [134, 135]. In fact, due to 
the high degree of conservation of cellular and molecular mechanisms between yeast and 
higher eukaryotes, S. cerevisiae has been used to study extremely complex signal 
transduction pathways, in which several cancer-related proteins are involved [136]. As a 
simpler eukaryotic organism, its genome was the first to be sequenced. It is well-known that 
at least 31% of the proteins encoded by the yeast genome have a human orthologue, and 
nearly 50% of human disease-related genes exhibit yeast orthologues (reviewed in [134, 
137]). Additionally, it presents some other advantages as a cell model to study human 
disease-related proteins, such as: easy and low-cost manipulation, short generation time, 
and high compliance to genetic manipulation, given its well-defined genetic system [134]. 
Nevertheless, as an unicellular organism, the impossibility to study disease aspects like 
multicellularity and cell-cell interactions represent the main limitation of this model [136]. 
Despite this, yeast has proven to greatly contribute to the clarification of complex cellular 
processes. Additionally, it has been considered an efficient first-line tool for genetic and 
chemical screenings that has greatly advanced the pharmacotherapy of several human 
diseases, specially of cancer [134]. 
The study of cancer-related proteins in the yeast model can involve the adoption of 
different approaches, which are highly dependent on the degree of conservation of the 
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protein of interest [136]. If the human gene implicated is conserved in yeast, its function can 
be directly studied in this organism. However, if the gene has no orthologues in yeast, its 
study is still possible by heterologous expression. This “humanized yeast” model allows the 
study of a human protein in a simplified eukaryotic environment, without the interference of 
other proteins with similar or overlapping functions, or its regulators [136]. This justifies the 
attractiveness of this cell model for uncovering major aspects of p53 family proteins [136]. 
In fact, no orthologues of each member of the p53 family, or of any of their endogenous 
negative modulators, have been identified in yeast so far [138]. 
Several yeast-based methodologies have been developed for functional, molecular 
and pharmacological studies of p53 family proteins. In 2003, the technique of functional 
analysis of separated alleles in yeast (FASAY) was developed to understand the 
transcriptional status of p53 in cancer cells, as described in [139]. Some modified versions 
of the FASAY assay allowed many different studies, including the identification of tumor-
derived p53 mutations, and the understanding how these mutations could interfere with the 
p53 function in human tumor cells [140]. This type of assays was also used to compare the 
transcriptional activity of p53 and p63 on CDKN1A, BAX and MDM2 response elements 
[141], and to analyze the ability of p53 mutants to inhibit the p73 transcriptional activity 
[142].  
More recently, a FASAY-derived dual-luciferase functional assay, based on the 
analysis of the p53 transcriptional activity using the Firefly luciferase reporter gene, was 
developed [143]. This assay has been used in parallel with mammalian cell-based assays, 
contributing to the investigation of the impact of small molecules and interacting proteins, 
such as MDM2 and 53BP1, on wt and mutant p53 transactivational activity [143] (Figure 
7A). In fact, the effectiveness of this assay was validated with the two aforementioned 
inhibitors of the p53-MDM2 interaction, nultin-3a [116] and RITA [121]. Later, similar yeast-
based transactivation assays were developed for p63 and p73 [144]. Actually, using these 
assays, Monti et al (2014) demonstrated that both TAp63α and ΔNp63α were 
transcriptionally active in yeast exhibiting intrinsic differences in transactivation specificities 
[145]. 
The yeast two-hybrid (Y2H) assay is the most well-known and used genetic assay 
to study protein-protein interactions. This assay takes advantage of the properties of the 
transcriptional factor GAL4, which is composed by two domains, a DNA-binding domain 
(DBD) and a transactivation domain (AD), that can be separated and individually fused to 
the interest proteins [146]. This assay was crucial to determine the amino acids of MDM2 
that are critical for binding to p53 [147] (Figure 7B). It was also decisive to reveal not only 
the interaction between the anti-apoptotic translationally controlled tumor protein (TCTP) 
and p53, but also the critical binding sites between them [148]. The Y2H also allowed the 
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study of interactions between ΔNp63 and wt/mutant p53 [149] and between TAp63 isoforms 
with other p53 family members [150]. Additionally, with the Y2H method, the analysis of the 
affinity between p63/p73 and MDMs became possible [150]. 
Yeast has been also widely used as a tool to study the role of p53 on cell growth 
and cell cycle. Nigro et al (1992) showed the induction of growth inhibition by human wt p53 
expressed in S. cerevisiae, which was markedly increased by the co-expression of human 
cell cycle regulated protein kinase CDC2Hs [151]. Latter, it was also demonstrated that the 
expression of wt p53 in yeast induced a marked growth inhibition associated with S-phase 
cell cycle arrest [152]. With this toxic effect of p53 in yeast, the development of yeast 
phenotypic assays, based on simple measurements of cell growth, was possible [152] 
(Figure 7C). In subsequent studies, the conservation in yeast of the inhibitory effect of 
MDM2 and MDMX on the p53 activity was demonstrated. Leão et al (2013) showed that the 
co-expression of p53 with MDM2 and MDMX significantly reduces the p53-dependent 
growth inhibition and cell cycle arrest in yeast [153, 154]. Additionally, it was proposed that 
ACT1 is a putative endogenous p53 target gene, based on the fact that the p53-induced 
yeast growth inhibition and cell cycle arrest were associated with an increase of actin protein 
levels, which was modulated by natural and chemical regulators of the p53 activity [153, 
154] (Figure 7C). These yeast growth inhibitory assays paved the way to the screening of 
genetic and chemical modulators of the p53 activity.  
 
 
Figure 7 – Schematic representation of different yeast models frequently used to study p53. 
(A) Yeast-based p53 dual-luciferase transactivation assay. These assays can use yeast cells 
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expressing human wt/mutant p53 or co-expressing human wt p53 and a co-factor (e.g., MDM2 or 
53BP1). The p53 transcriptional activity is assessed by quantification of the luciferase activity, which 
is directly proportional to the light units measured in a plate reader. (B) Yeast two-hybrid assay. In 
this assay, the coding sequence of protein X (Bait) is fused to the GAL4-DBD and the coding 
sequence of protein Y (Prey) is fused to the GAL4-AD. Upon co-expression, protein-protein 
interaction is detected because the reconstitution of the transcription factor leads to the expression 
of a reporter gene. (C) Yeast p53-MDMs phenotypic assay. The expression of wt p53 induces 
growth inhibition and cell cycle arrest, and increases the actin protein levels, effects that are 
abolished by both MDM2 and MDMX. 
 
Once developed, these yeast phenotypic assays were used to search for new 
inhibitors of the p53 interaction with MDM2/MDMX. In fact, using these assays, new small 
molecule inhibitors of the p53-MDM2 interaction with a xanthone scaffold, such as 
pyroxanthone 1 [154], α-mangostin and gambogic acid [155], and more recently, with an 
oxazoloisoindolinone scaffold [156], were identified. In addition, using the same screening 
approach, the dual inhibitor of the p53 interaction with MDM2 and MDMX, the (S)-
tryptophanol derivative OXAZ-1, was identified from a small library of enantiopure 
tryptophanol-derived oxazolopiperidone lactams [128].  
More recently, the effects of human p63 and p73 on cell proliferation and death, as 
well as the interference of both MDMs on their activities, were also studied in yeast [157]. 
In this work, it was demonstrated that TAp63, ΔNp63 and TAp73-α isoforms induced a yeast 
growth inhibition associated with S-phase cell cycle arrest, and increased actin expression 
levels. Furthermore, MDM2 and MDMX inhibited the activity of all tested p53 family 
members in yeast, being their effects weaker on TAp63 activity, as observed in mammalian 
cells [103]. Moreover, nutlin-3a and SJ-172550 were identified as potential inhibitors of the 
p73 interaction with MDM2 and MDMX, respectively. 
Collectively, accumulating data have supported the use of the yeast model as an 
effective tool for biological and pharmacological studies of p53 family proteins.  
 
 
1.5. AIMS OF RESEARCH 
As exposed above, the p53 family proteins are key therapeutic targets in anticancer 
treatment. This justifies the amazing research performed over the last years around this 
family of proteins. Despite this, the high complexity of the p53 family pathway, particularly 
of the molecular mechanisms regulating the interplay between the distinct isoforms of this 
family, justifies that major issues about the pharmacology and biology of these proteins 
(especially of p63 and p73) remain unclear.  
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With the present thesis, we aimed to bring new advances into the pharmacology of 
p53 family proteins. Most importantly, we envisioned identifying new anticancer drug 
candidates that may represent new hopes and therapeutic opportunities in the treatment of 
cancer. To achieve such goals, it was intended to:  
i) Elucidate the molecular mechanism of action of LEM2, an optimized derivative of 
the pyroxanthone 1 previously identified as an inhibitor of the p53-MDM2 interaction [154]; 
ii) Validate, in human tumor cell lines and animal models, the molecular mechanism 
of action of a potential dual inhibitor of the p53-MDM2/MDMX interactions, previously 
identified in yeast p53-MDMs screening assays. 
 
  
 
II 
Materials and Methods 
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2. MATERIALS AND METHODS 
 
 
2.1. COMPOUNDS 
Nutlin-3a was obtained from Alexis Biochemicals (Grupo Taper, Sintra, Portugal). 
Doxorubicin, SJ-172550 were obtained from Sigma-Aldrich (Sintra, Portugal). The xanthone 
derivative 1-carbaldehyde-3,4-dimethoxy-9H-xanthen-9-one (LEM2) was synthesized, 
according to described procedures [154], by Prof. Emília Sousa (CIIMAR, FFUP). The 
enantiopure phenylalaninol-derived oxazolopyrrolidone lactam derivative JL-1 was 
synthesized, according to the described procedures [156], by Prof. Maria Santos 
(iMed.ULisboa, FFUL).  All tested compounds were dissolved in dimethylsulfoxide (DMSO; 
Sigma-Aldrich; Sintra, Portugal).  
 
 
2.2. YEAST CELLS 
 
2.2.1. YEAST TARGETED SCREENING ASSAY 
Saccharomyces cerevisiae (strain CG379 Matα, ade5, his2, leu2-112, trp1-289, 
ura3-52; Kil-O) (Yeast Genetic Stock Center, University of California, USA) expressing 
human p53 or TAp73α alone and combined with human MDM2 were obtained in previous 
works [157]. For expression of human proteins, cells were diluted to 0.05 optical density at 
600 nm (OD600) in induction selective medium with 2% (w/w) galactose (Sigma-Aldrich, 
Sintra, Portugal), 1% (w/w) raffinose (Acros Organics; JMGS, Odivelas, Portugal), 0.7% 
(w/w) yeast nitrogen base without amino acids from Difco (Quilaban, Sintra, Portugal), and 
all the amino acids required for yeast growth (50 mg/mL) except leucine and tryptophan. 
Yeast cells were incubated at 30 ºC, under continuous orbital shaking (200 r.p.m.). Co-
transformed yeast cells were incubated in selective induction medium in the presence of 
0.1 - 50 μM nutlin-3a (positive control), 1-100 μM xanthone derivative LEM2, or 0.1% DMSO 
only, until 0.4 OD600 achieved with control yeast (transformed with the empty vectors 
incubated with DMSO only). Yeast growth was analyzed by counting the number of colony-
forming units (CFU) per mL (CFU/mL) after 2 days incubation at 30 ˚C on Sabouraud 
Dextrose Agar from Liofilchem (Frilabo, Porto, Portugal). 
 
2.2.2. YEAST CELL CYCLE ANALYSIS 
Flow cytometric analysis of DNA content was performed using Sytox Green Nucleic 
Acid, as described in [152]. Briefly, 1 x 107 cells were fixed in 70% (v/v) ethanol, incubated 
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with 250 μg/mL RNase A (Sigma-Aldrich, Sintra, Portugal) and 1 mg/mL proteinase K 
(Sigma-Aldrich, Sintra, Portugal), and further incubated with 10 μM Sytox Green Nucleic 
Acid from Invitrogen (Alfagene, Carcavelos, Portugal). 
 
 
2.3. HUMAN TUMOR CELL LINES 
 
2.3.1. HUMAN TUMOR CELL LINES AND GROWTH CONDITIONS 
The human colon adenocarcinoma HCT116 cell line harboring wt p53 (HCT116 
p53+/+) and its isogenic derivative, in which p53 has been knocked out (HCT116 p53-/-), the 
human breast adenocarcinoma MCF-7, and the osteosarcoma SJSA-1 cell lines were kindly 
provided by Dr. A. Inga (University of Trento, Italy). Cell lines were routinely cultured in 
RPMI with ultraglutamine medium from Lonza (VWR, Carnaxide, Portugal) supplemented 
with 10% fetal bovine serum from Gibco (Alfagene, Carcavelos, Portugal), and maintained 
in a humidified incubator at 37 °C with 5% CO2 in air. 
 
2.3.2. SULFORHODAMINE B (SRB) ASSAY 
For the analysis of the effect of compounds on the in vitro growth of human tumor 
cells, 5 x 103 cells/well were plated in 96-well plates and incubated for 24 h. Cells were then 
exposed to serial dilutions of compounds (from 0.12 to 50 μM). The effect of compounds 
was analyzed following 48 h incubation, using the SRB assay. Briefly, following fixation with 
10% trichloroacetic acid (Sigma-Aldrich, Sintra, Portugal), plates were stained with 0.4% 
SRB (Sigma-Aldrich, Sintra, Portugal) and washed with 1% acetic acid (Sigma-Aldrich, 
Sintra, Portugal). The bound dye was then solubilized with 10 mL Tris-Base and the 
absorbance was measured at 510 nm in a microplate reader (Biotek Instruments Inc., 
Synergy MX, USA). The solvent of compounds (DMSO) corresponding to the maximum 
concentration used in these assays (0.25%) was included as control. The concentration of 
compound that causes a 50% reduction in the net protein increase in cells (GI50, growth 
inhibition of 50%) was determined for all tested compounds. 
 
2.3.3. ANALYSIS OF CELL CYCLE AND APOPTOSIS 
Human tumor cells were plated in 6-well plates at a final density of 1.5 x 105 cells/well 
and incubated for 24 h. Cells were then treated with the GI50 and/or with twice the GI50 
(2xGI50) concentration of compounds, or DMSO only for 24 or 48 h. For cell cycle analysis, 
cells were fixed in ice-cold 70% ethanol and incubated at 37 ºC with RNase A (Sigma-
Aldrich, Sintra, Portugal) at a final concentration of 20 μg/mL for 15 min, and further 
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incubated with 50 μg/mL propidium iodide (PI) from Molecular Probes (Alfagene, 
Carcavelos, Portugal) for 30 min, followed by flow cytometric analysis. For apoptosis 
analysis, cells were analyzed by flow cytometry using the Annexin V-FITC Apoptosis 
Detection Kit I from BD Biosciences (Enzifarma, Porto, Portugal), according to the 
manufacturer’s instructions. Briefly, human tumor cells were suspended in binding buffer 
and then incubated with 5 μL of FITC-Annexin V and 5 μL of PI for 15 min at room 
temperature. Cells were then analyzed by flow cytometry. 
 
2.3.4. WESTERN BLOT ANALYSIS 
To prepare the whole protein extracts from human tumor cells, cells were lysed with 
RIPA buffer containing EDTA-free protease inhibitor cocktail from Sigma-Aldrich (Sintra, 
Portugal). For mitochondrial and cytosolic fractions of human tumor cells, the Mitochondrial 
Fractionation Kit from Active Motif (Frilabo, Porto, Portugal) was used according to the 
manufacturer’s instructions. 
Whole protein extracts were quantified using the Coomassie staining Bradford from 
Sigma-Aldrich (Sintra, Portugal). Proteins (40 μg) were electrophoresed using a 10% SDS-
PAGE and transferred to a Whatman nitrocellulose membrane from Protan (VWR, 
Carnaxide, Portugal). Membranes were blocked with 5% milk and probed with a mouse 
monoclonal anti-p53 (DO-1), anti-MDM2 (D-12), anti-Bax (2D2), anti-PUMA (B-6), anti-
PARP (C2-10), and anti-cytochrome c (A-8) followed by an anti-mouse horseradish-
peroxidase (HRP)-conjugated secondary antibody. For p73, p21 and MDMX detection, 
membranes were probed with a rabbit polyclonal anti-p73 (AB7824), anti-p21 (C-19) and 
anti-MDMX (A300-287A), respectively, followed by an anti-rabbit HRP-conjugated 
secondary antibody. For loading control, membranes were stripped and reprobed with a 
mouse monoclonal anti-GAPDH (6C5). For analysis of mitochondrial and cytosolic fractions, 
membranes were reprobed with the loading controls mouse monoclonal anti-GAPDH (6C5) 
or anti-Cox4 (F-8), used to exclude putative contamination of cytosolic and mitochondrial 
fractions, respectively. All antibodies were purchased from Santa Cruz Biotechnology 
(Frilabo, Porto, Portugal), except the anti-MDMX obtained from Bethyl Laboratories 
(bioNova cientifica, Madrid, Spain), and anti-p73 obtained from Millipore (Grupo Taper, 
Sintra, Portugal). The signal was detected with the ECL Amersham kit from GE Healthcare 
(VWR, Carnaxide, Portugal) and with the Kodak GBX developer and fixer from Sigma-
Aldrich (Sintra, Portugal).  
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2.3.5. CO-IMMUNOPRECIPITATION (CO-IP) ASSAY 
The co-IP assay was performed using the Pierce Classic Magnetic IP and Co-IP Kit 
from Thermo scientific (Dagma, Carcavelos, Portugal), according to the manufacturer’s 
instructions. Briefly, cells were plated at the final density of 5 x 105 cells/plate and incubated 
for 24 h. Cells were then treated with 2.88 and 3.60 μM LEM2, 7 and 14 μM JL-1 or DMSO 
only for 24 h. After cell lysis and protein lysate separation, 500 μg of total protein was 
incubated with a rabbit polyclonal anti-p73 from Millipore (Grupo Taper, Sintra, Portugal), 
with a mouse monoclonal anti-p53 (DO-1), or with a mouse immunoglobulin G (IgG, control) 
from Santa Cruz Biotechnology (Frilabo, Porto, Portugal), for 12 h at 4 ˚C. 
Immunocomplexes were precipitated using magnetic beads. Detection of p53, p73, MDM2, 
MDMX, and GAPDH (loading control) in whole cell lysate (input) and immunoprecipitated 
fraction was performed by Western blot analysis as described in section 2.3.4. 
 
2.3.6. ANALYSIS OF MITOCHONDRIAL MEMBRANE POTENTIAL (ΔΨM) 
Analysis of Δψm was performed by flow cytometry. Tumor cells were plated in 6-well 
plates at a final density of 1.5 x 105 cells/well. After 24 h incubation, HCT116 p53-/- cells 
were treated with the GI50 concentration of LEM2 or DMSO only for 8 h. Cells were 
harvested and incubated with 1 nM 3,3'-Dihexyloxacarbocyanine Iodide, DiOC6(3), from 
Alfagene (Molecular probes, Carcavelos, Portugal), for 30 min at 37 °C; cells treated with 
50 μM carbonilcyanide p-triflouromethoxyphenylhydrazone (FCCP; Sigma-Aldrich, Sintra, 
Portugal), for 15 min at 37 ºC, were used as positive control of dissipation of Δψm.  
 
2.3.7. ANALYSIS OF REACTIVE OXYGEN SPECIES (ROS) GENERATION 
Analysis of intracellular ROS generation was performed by flow cytometry. Briefly, 
tumor cells were plated in 6-well plates at a final density of 1.5 x 105 cells/well and incubated 
for 24 h. Cells were treated with the GI50 concentration of LEM2 or DMSO only for 48 h. 
Cells were harvested and stained with 10 μM H2DCFDA from Life Technologies (Alfagene, 
Carcavelos, Portugal), for 30 min at 37 ºC. 
 
2.3.8. GENOTOXICITY STUDIES BY MICRONUCLEUS ASSAY 
Genotoxicity was analyzed by cytokinesis-blocked micronucleus assay in 
lymphocytes as described in [158]. Fresh peripheral blood samples were collected from 
healthy volunteers into heparinized vacutainers. Blood samples, suspended in RPMI 
medium supplemented with 10% FBS, were treated with the GI50, 2xGI50 and 3xGI50 
concentrations of JL-1, LEM2, DMSO only or 1μg/mL cyclophosphamide (known mutagenic 
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agent; positive control; Sigma-Aldrich, Sintra, Portugal) for 44 h. Cells were thereafter 
treated with 3 μg/mL cytochalasin B (cytokinesis preventive; Sigma-Aldrich, Sintra, 
Portugal) for 28 h. Lymphocytes were isolated by density gradient separation (Histopaque-
1077 and -1119; Sigma-Aldrich, Sintra, Portugal), fixed in 3:1 methanol/glacial acetic acid, 
and stained with Wright stain (Sigma-Aldrich, Sintra, Portugal). For each sample, 1000 
binucleated lymphocytes were blindly scored using a Leica light optical microscope 
(Wetzlar); the number of micronuclei per 1000 binucleated lymphocytes was recorded. 
 
2.3.9. IN VITRO MIGRATION ASSAYS  
The impact of JL-1 on migration of HCT116 p53+/+ cell lines was studied performing 
an in vitro migration assay, commonly used as a parameter of in vivo tumor cell 
invasiveness: the Wound Healing Scratch assay [159]. In this assay, about 5 x 105 cells/well 
were grown to confluence in 6-well plates for 24 hours. Using a sterile 200 μL tip, a fixed-
width wound was created in the cell monolayer and the GI10 concentration of JL-1 (or DMSO 
only) was added to medium. Cells were thereafter photographed at different time-points of 
treatment, using the Microscope AE 2000 from Motic, and the Digital Camera Motican 5MP, 
until complete closure of the wound.  
 
2.3.10. IN VIVO EXPERIMENTS 
Xenograft tumor assays were performed with human HCT116 p53+/+ and HCT116 
p53-/- tumor cell lines in BALB/c Nude mice purchased from Charles-River Laboratories 
(Barcelona, Spain) and housed under pathogen free conditions in individual ventilated 
cages. Briefly, 1 x 106 HCT116 cells (in PBS) were inoculated subcutaneously in the dorsal 
flank of each mice. Tumor dimensions were assessed by caliper measurement and their 
volumes were calculated (tumor volume = (length  width2) / 2). Treatment was started when 
tumors reached volumes of approximately 100 mm3 (which occurred 14 days after the 
grafts). Mice were then treated twice a week with 50 mg/kg JL-1 or vehicle (control) by 
intraperitoneal injection during two weeks. Tumor volumes and body weights were 
monitored twice a week until the end of the treatment. Animals were sacrificed by cervical 
dislocation at the end of the study or when tumors reached 1500 mm3 or the animals present 
any signs of morbidity. After sacrifice, tumors were removed and photographed. The 
following number of animals was used: HCT116 p53+/+ and HCT116 p53-/- cell lines (Control-
6, Treatment-6). 
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2.4. YEAST AND HUMAN TUMOR CELL LINES 
 
2.4.1. FLOW CYTOMETRIC DATA ACQUISITION AND ANALYSIS 
For the flow cytometric analysis the AccuriTM C6 flow cytometer from BD 
Biosciences (Enzifarma, Porto, Portugal) and the CellQuest software from BD Biosciences 
(Enzifarma, Porto, Portugal) were used. Cell cycle phases were identified and quantified 
using ModFit LT software (Verity Software House Inc., Topsham, USA). 
 
2.4.2. STATISTICAL ANALYSIS 
Data were analyzed statistically using the GraphPad software. Differences between 
means were tested for significance using the Student’s t-test (*p < 0.05; **p < 0.01; ***p < 
0.001). 
 
 
 
 
 
 
 
 
 
  
 
III 
LEM2: a new small molecule 
inhibitor of the p73-MDM2 
interaction  
  
 
 
 39 
 
3. LEM2: A NEW SMALL MOLECULE INHIBITOR OF THE P73-
MDM2 INTERACTION 
 
Xanthones are phenolic compounds well-known for their multiple functions, 
including anticancer activities (reviewed in [160]). In the last years, several molecular 
modifications in the tricyclic xanthone scaffold have led to compounds with increased in 
vitro growth inhibitory activity against a wide range of tumor cells (reviewed in [160, 161]), 
particularly with wt p53 and overexpressed MDM2 [162, 163]. Additionally, the anti-tumor 
activity of two natural xanthones, such as gambogic acid and α-mangostin, has been 
related to the activation of a p53-dependent pathway in several works [164-166].  
More recently, a work performed by our group led to the identification of 
pyranoxanthone 1 (LEM1; 3,4-dihydro-12-hydroxy-2,2-dimethyl-2H,6H-pyrano(3,2-
b)xanthen-6-one) (Figure 8) as the first inhibitor of the p53-MDM2 interaction with a 
xanthone scaffold [154]. In that work, using a yeast p53-MDM2 interaction screening 
assay, the activity of a library of xanthone derivatives on the p53-MDM2 interaction was 
investigated. Among the tested xanthones, LEM1 significantly reduced the MDM2 
inhibitory effect on the p53 activity. The effect of this compound was also analyzed in wt 
p53-expressing human tumor cell lines, as breast adenocarcinoma MCF-7 and colon 
adenocarcinoma HCT116 cell lines. In accordance with what was observed in yeast, 
LEM1 mimicked the activity of the known small molecule inhibitor of the p53-MDM2 
interaction, nutlin-3a, in human tumor cells, leading to the successful activation of p53 
and downstream cell signaling [154]. 
 In the present thesis, the molecular mechanism of action of LEM2, a LEM1 
derivative, was investigated in order to obtain an optimized inhibitor of the p53-MDM2 
interaction. Despite this initial aim, the results obtained showed that LEM2 was not an 
inhibitor of the p53-MDM2 interaction, but instead it was an inhibitor of the p73-MDM2 
interaction.  
 
             
Figure 8 – Chemical structure of 3,4-dihydro-12-hydroxy-2,2-dimethyl-2H,6H-pyrano(3,2-
b)xanthen-6-one (LEM1). 
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3.1. RESULTS 
 
3.1.1. LEM2 DOES NOT INTERFERE WITH THE P53-MDM2 INTERACTION  
The effect of LEM2 as inhibitor of the p53-MDM2 interaction was analyzed using 
a previously developed yeast assay to search for inhibitors of this interaction [154]. 
These yeast assays are based on the fact that the human wt p53 induces a marked 
growth inhibition, associated with S-phase cell cycle arrest, in S. cerevisiae, which is 
abolished by human MDM2. As in mammalian cells, inhibitors of the p53-MDM2 
interaction reduce the impact of MDM2 on the p53 activity, leading to the restoration of 
the p53-induced yeast growth inhibition [152]. The efficiency of this yeast assay was 
validated through the recent identification of LEM1 as an inhibitor of the p53-MDM2 
interaction [154]. Using this approach, the effect of 1-100 μM LEM2 was compared to 
that obtained with the positive control, nutlin-3a. For the tested concentration range, 
LEM2 did not reduce the negative effect of MDM2 on the p53-induced growth inhibition 
(data not shown).  
Despite the results obtained in yeast, the tumor cell growth inhibitory effect of 
LEM2, and the involvement of the p53 pathway in its activity, was analyzed. For that, 
HCT116 cell lines with wt p53 (HCT116 p53+/+) and its p53-null isogenic derivative 
(HCT116 p53-/-) were used. The GI50 values obtained for LEM2 in p53+/+ and p53-/- 
HCT116 cells (Table 2) indicated that this small molecule strongly inhibited the growth 
of both tumor cell lines. Additionally, contrary to nutlin-3a, no significant differences in 
the growth inhibitory effect of LEM2 were observed between p53+/+ and p53-/- HCT116 
cells (Table 2). This result indicated that the p53 pathway was not involved in the anti-
tumor activity of LEM2.  
 
Table 2 – GI50 values obtained for nultin-3a and LEM2 in human colon adenocarcinoma HCT116 
tumor cell lines.  
Compounds 
GI50 (μM)a 
HCT116 p53+/+ HCT116 p53-/- 
Nutlin-3a 3.67 ± 0.34 24.0 ± 0.7* 
LEM2 0.64 ± 0.01 0.72 ± 0.02 
a The GI50 was determined for all tested compounds after 48 h incubation, using the SRB assay. 
Cells were exposed to serial dilution of nutlin-3a (positive control; from 0.62 to 50 μM) or LEM2 (from 0.12 
to 10 μM). Data are mean ± S.E.M. of three independent experiments. Values significantly different from 
HCT116 p53+/+ (*p < 0.05). 
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In order to confirm the results obtained in yeast, the ability of LEM2 to block the 
p53-MDM2 interaction was assessed using the co-IP assay, in HCT116 p53+/+ tumor 
cells. It was shown that 2.56 and 3.20 μM LEM2 (corresponding to 4xGI50 and 5xGI50 
concentrations, respectively) did not interfere with the amount of MDM2 co-
immunoprecipitated with p53 (Figure 9). This result supported the absence of effect of 
LEM2 on the p53-MDM2 interaction. 
 
 
Figure 9 – LEM2 did not disrupt the p53-MDM2 interaction in HCT116 p53+/+ cells. HCT116 
p53+/+ cells were treated with 2.56 and 3.20 µM LEM2 or DMSO only for 24 h. HCT116 p53+/+ 
cells lysates were immunoprecipitated (IP) with p53 or mouse immunoglobulin G (IgG) antibodies, 
followed by immunoblotting with MDM2 and p53 antibodies; whole cell lysate (input); immunoblots 
are representative of two independent experiments; GAPDH was used as loading control. 
 
 
3.1.2. IDENTIFICATION OF LEM2 AS A POTENTIAL INHIBITOR OF THE P73-MDM2 
INTERACTION USING THE YEAST SCREENING ASSAY 
Since HCT116 p53-/- tumor cells are also p63-null cells [131] (also confirmed by 
Western blot analysis; data not shown), it was hypothesized if LEM2 could interfere with 
the p73 pathway. To address this issue, a yeast-based assay previously developed to 
search for inhibitors of the p73-MDM2 interaction [157] was used. Like for p53, in this 
assay, although the expression of human MDM2 does not interfere with the yeast cell 
growth and cell cycle progression, its co-expression with p73 significantly reduces the 
p73-induced yeast growth inhibition (Figure 10A and 10B) and cell cycle arrest (Figure 
10C). The efficiency of this yeast assay was validated by testing nutlin-3a (a known 
inhibitor of the p73-MDM2 interaction) [157]. Using this approach, the effect of 0.1 – 50 
μM LEM2 on the reversion of p73-induced yeast growth inhibition by MDM2 was 
evaluated. From the concentration-response curves obtained, it was shown that LEM2 
presented similar effects to nutlin-3a with reversion of the MDM2-inhibitory effect (Figure 
10A). Similarly to nultin-3a, when yeast cells co-expressing p73 and MDM2 were treated 
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with 10 μM LEM2 for 40 h, approximately 98% and 72% of the p73-induced growth 
inhibition (Figure 10B) and S-phase cell cycle arrest (Figure 10C), respectively, were re-
established without interfering with the activity of p73 or MDM2 when expressed alone. 
These results showed that LEM2 was able to inhibit the negative effect of MDM2 on p73, 
behaving as a potential inhibitor of the p73-MDM2 interaction in yeast. 
 
 
Figure 10 – LEM2 reduces the inhibitory effect of MDM2 on p73 activity in yeast. (A) Effect 
of 0.1 – 50 μM LEM2 and nutlin-3a on the reversion of p73-induced yeast growth inhibition by 
MDM2, after 42 h incubation. The growth of yeast cells co-expressing p73 alone and MDM2 was 
evaluated by CFU counts; results were plotted setting as 100% the growth achieved with yeast 
cells expressing p73 alone with DMSO only; data are mean ± S.E.M. of five independent 
experiments; values significantly different from DMSO only are indicated (***p < 0.001). (B) 
Effects of 10 μM nutlin-3a and 10 μM LEM2 on the growth of control yeast, yeast expressing only 
p73 or MDM2, and yeast co-expressing p73 and MDM2, after 40 h incubation. Results were 
estimated considering 100% growth the number of CFU obtained with control yeast (empty 
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vectors). Data are mean ± S.E.M. of five independent experiments; values obtained with yeast 
co-expressing p73 and MDM2 treated with the compound significantly different from DMSO only 
are indicated (*p < 0.05). (C) Effects of 10 μM nutlin-3a and 10 μM LEM2 on the yeast cell cycle 
progression of control yeast, yeast expressing only p73 or MDM2, and yeast co-expressing p73 
and MDM2, after 40 h incubation. Yeast cell cycle phases were quantified by flow cytometry; data 
are mean ± S.E.M. of three independent experiments; values significantly different from DMSO 
only are indicated (*p < 0.05). 
 
 
3.1.3. LEM2 ACTIVATES THE P73 PATHWAY IN HUMAN TUMOR CELLS THROUGH 
INHIBITION OF THE P73-MDM2 INTERACTION 
The molecular mechanism of action of LEM2, as a potential inhibitor of the p73-
MDM2 interaction, was thereafter ascertained in the p53- and p63-null HCT116 cells. 
The results obtained showed that the growth inhibitory effect of LEM2, at GI50 
concentration, was associated with the induction of G2/M-phase cell cycle arrest (Figure 
11A) and apoptosis (Figure 11B), with PARP cleavage (Figure 11C). 
 
Figure 11 – LEM2 induces cell cycle arrest, apoptosis and PARP cleavage in HCT116 p53-
/- cells. (A) LEM2-induced cell cycle arrest was determined after 24 h treatment with 0.72 µM 
LEM2. Cell cycle phases were analyzed by flow cytometry using PI staining; data are mean ± 
S.E.M. of three independent experiments; values significantly different from DMSO are indicated 
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(*p < 0.05). (B) LEM2-induced apoptosis was determined after 48 h treatment with 0.72 µM LEM2. 
Apoptosis was analyzed by flow cytometry using FITC-Annexin V and PI; data are mean ± S.E.M. 
of three independent experiments; values significantly different from DMSO are indicated (*p < 
0.05). (C) LEM2-induced PARP cleavage was analyzed by Western blot after 48 h treatments 
with 0.72 µM LEM2 or DMSO only; immunoblots are representative of two independent 
experiments; GAPDH was used as loading control. 
 
Additionally, it was observed that 0.72 μM LEM2 led to ROS generation (Figure 
12A) and ∆ψm dissipation (Figure 12B) in HCT116 p53-/- cells.  
 
 
Figure 12 – LEM2 induces ROS generation and ∆ψm dissipation in HCT116 p53-/- cells. (A) 
LEM2-induced ROS generation was determined after 48 h treatment with 0.72 µM LEM2. (B) 
LEM2-induced ∆ψm dissipation was determined after 8 h treatment with 0.72 µM LEM2. In (A) and 
(B), for the assessment of ROS generation and ∆ψm, cells were stained with H2DCFDA and 
DIOC6(3), respectively, and analyzed by flow cytometry; FCCP (C+) was used as positive control; 
histograms are representative of two independent experiments; M2 cursor indicates the 
subpopulation analyzed; Δ values correspond to the increase in the percentage of H2DCFDA 
positive cells (A) and of cells with ∆ψm dissipation (B) after treatment with LEM2. 
 
To assess the activation of the p73 pathway by LEM2, the protein expression 
levels of p73 and of its target genes, such as MDM2, p21 and Bax, were checked by 
Western blot analysis in HCT116 p53-/- cells. The results obtained showed that 0.72 μM 
LEM2 increased the expression levels of the p73, MDM2, p21 and Bax (Figure 13A). 
Together, these results supported the reactivation of the p73 pathway in tumor cells.  
Since LEM2 led to ∆ψm dissipation and increased Bax production, it was 
hypothesized if this compound could induce a p73-dependent mitochondria-mediated 
apoptotic pathway. For that purpose typical events of a mitochondrial apoptotic pathway, 
such as Bax translocation to mitochondria and cyt c release from the mitochondria to 
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cytosol, were checked in p53-null tumor cells treated with 0.72 μM LEM2. However, 
LEM2 did not trigger any of these events (data not shown). 
The ability of LEM2 to block the p73 interaction with MDM2 was thereafter 
demonstrated by co-IP assay, in HCT116 p53-/- cells. In fact, at 3.60 μM (corresponding 
to 5xGI50 concentration), a visible decrease of the amount of MDM2 co-
immunoprecipitated with p73 was observed (Figure 13B). These results confirmed that 
LEM2 was an inhibitor of the p73-MDM2 interaction. 
 
 
Figure 13 – LEM2 increases the expression levels of p73 and up-regulates p73 target genes 
by blocking the p73 interaction with MDM2 in HCT116 p53-/- cells. (A) Western blot analysis 
was performed after 24 h treatment with 0.72 µM LEM2 or DMSO only. Immunoblots are 
representative of two independent experiments; GAPDH was used as loading control. (B) 
HCT116 p53-/- cells were treated with 2.88 and 3.60 µM LEM2 or DMSO only for 24 h. HCT116 
p53-/- cells lysates were immunoprecipitated (IP) with p73 or rabbit immunoglobulin G (IgG) 
antibodies, followed by immunoblotting with MDM2 and p73 antibodies; whole cell lysate (input); 
immunoblots are representative of two independent experiment; GAPDH was used as loading 
control. 
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3.1.4. LEM2 HAS NO IN VITRO GENOTOXICITY  
Genotoxicity refers to the capacity of a substance to damage the genetic 
information within a cell. The assessment of a genotoxic potential of a certain compound 
is typically determined in an early phase of drug development process, as an important 
part of hazard identification [167]. The genotoxicity of LEM2 was cytogenetically tested 
by assessing its ability to induce micronucleus (MN) in cultured peripheral lymphocytes 
of normal individuals. In fact, when compared to samples treated with DMSO only, 0.72, 
1.44 and 2.16 μM LEM2 (corresponding to GI50, 2xGI50 and 3xGI50 concentrations, 
respectively) did not increase the number of MN in lymphocytes (Figure 14). These 
results showed that LEM2 has no apparent in vitro genotoxic activity. 
 
 
Figure 14 – LEM2 has no in vitro genotoxicity. The induction of micronucleus (MN) was tested 
in cultured peripheral lymphocytes of normal individuals, after 44 h treatment with LEM2, DMSO 
or cyclophosphamide, using cytokinesis-blocked micronucleus assay. The number of MN per 
1000 binucleated lymphocytes. Cells were treated 1 μg/mL cyclophosphamide were used a 
positive control (C+); data are mean ± S.E.M. of three independent experiments; values 
significantly different from DMSO are indicated (***p < 0.001). 
 
 
3.2. DISCUSSION 
 The tight regulation of p53 by MDM2, via an autoregulatory feedback loop, is a 
well-known process [83, 84]. As mentioned above, MDM2 also binds to other p53 family 
proteins, such as p73, repressing its transcriptional activity [97]. p73 plays an important 
role in chemosensitivity of cancer cells, particularly when p53 is inactivated or absent. In 
fact, several studies referred that cisplatin and gamma-irradiation treatment lead to p73 
stabilization and enhanced apoptosis in cell lines, such as HCT116, Saos-2 and mouse 
fibroblasts 3T3 cells  (reviewed in [168]). In this manner, the activation of the p73 tumor 
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suppressive activity, through inhibition of MDM2, represents an appealing anticancer 
therapeutic strategy. In 2008, Lau et al showed that p53-null and mutant p53-expressing 
cells were also sensitive to the inhibitor of the p53-MDM2 interaction, nutlin-3a, which 
suggested the activation of a p53-independent pathway by this compound [131]. These 
authors proved that nutlin-3a was also an inhibitor of the p73-MDM2 interaction, causing 
p73 accumulation and inducing the expression of p73 transcriptional targets [131]. 
Actually, these results were in accordance with the fact that p73 binds to the same 
hydrophobic pocket of MDM2 targeted by nulin-3a [98]. 
 With this work, we intended to elucidate the molecular mechanism of an 
optimized derivative of LEM1, a compound previously identified by our group as an 
inhibitor of the p53-MDM2 interaction [154]. For that, a yeast-based screening assay was 
used to study the effect of LEM2 on p53-MDM2 interaction. However, surprisingly, the 
compound LEM2 had no impact on the p53-MDM2 interaction in yeast. Accordingly, this 
compound presented a p53-independent growth inhibitory effect and did not block the 
p53-MDM2 interaction in p53-expressing tumor cells. Despite this, LEM2 exhibited a 
potent growth-inhibitory effect in p53- and p63-null tumor cells, suggestive of a possible 
involvement of the p73 pathway in its activity. Based on this, and on the reported 
inhibitory ability of nultin-3a to block the p73-MDM2 interaction [131], the effect of LEM2 
on the p73-MDM2 interaction was checked using a yeast-based assay previously 
developed by our group to search for inhibitors of this interaction [157]. As expected, 
LEM2 behaved as an inhibitor of the p73-MDM2 interaction in yeast. In order to confirm 
the results obtained in yeast, the activation of a p73 pathway by LEM2 was checked in 
p53- and p63-null tumor cells. In accordance with yeast, in these tumor cells, LEM2 led 
to p73 activation and stabilization, which is in agreement with the reduction of the MDM2 
inhibitory effect on p73. In fact, LEM2 led to the activation of the p73 pathway through 
inhibition of the p73 interaction with MDM2.  
 By analysis of cell cycle progression and Annexin-V staining, it was also observed 
that LEM2 tumor growth-inhibitory effect was associated with the induction of a G2/M-
phase cell cycle arrest and apoptosis, which is in accordance with the increase of p21 (a 
major cell cycle regulator) and Bax (a pro-apoptotic protein of the Bcl-2 family) protein 
levels, as well as with PARP cleavage (a well-established substrate for caspase-3, during 
apoptosis) [169, 170]. Additionally, LEM2 induced ROS generation and ∆ψm dissipation, 
processes closely related to the activation of a mitochondria-mediated apoptotic 
pathway. Mitochondria-targeted agents have been widely recognized due to their high 
efficiency against chemotherapy-refractory cancer cells. In fact, drug-induced 
mitochondrial-apoptotic pathway has been considered an appealing anticancer strategy 
due to the high susceptibility of cancer cells to mitochondrial perturbations when 
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compared to their normal counterparts [170]. As reported for p53, p73 was also shown 
to induce a mitochondria-mediated apoptosis either by the direct transactivation of the 
Bax promoter, increasing its protein levels, or by an indirect mechanism mediated by the 
induction of Puma, which in turn promotes Bax mitochondrial translocation (reviewed in 
[171]). In physiological conditions, Bax exists as an inactive monomer in the cytosol, but, 
upon stress stimuli, Bax oligomerizes and translocates to the mitochondria, where it 
triggers ∆ψm dissipation and MOMP, ultimately leading to cyt c release and caspase 
activation [171]. In conformity with this, LEM2 was explored as an inducer of a p73-
dependent mitochondria-mediated apoptotic cell death. However, despite inducing ∆ψm 
dissipation and increased Bax production, LEM2 did not trigger Bax translocation to 
mitochondria and the release of cyt c to cytosol, for several different experimental 
conditions tested (concentrations of LEM2, treatment periods, among others). These 
results demonstrated that LEM2 does not induce a p73-dependent mitochondria-
mediated apoptotic pathway in human tumor cells. Lastly, LEM2 showed to be a non-
genotoxic compound. 
 Further work is still underway to support the activation of a p73-dependent 
pathway by LEM2, and to check the binding site of this compound. The inability of LEM2 
to inhibit the p53-MDM2 interaction, in opposition to nutlin-3a that binds to MDM2, lead 
us to hypothesize that LEM2 may probably bind to p73 instead of MDM2. Despite this, 
relevant insights about the mode of action of this compound are already provided in this 
study. 
 In conclusion, in this work, a new inhibitor of the p73-MDM2 interaction with 
potent tumor growth inhibitory effect was identified. To our knowledge, LEM2 represents 
the second inhibitor of the p73-MDM2 interaction reported until present, exhibiting a 
much higher potency than the reported nutlin-3a in p53-null tumor cells. Great 
therapeutic applications can be therefore envisioned for LEM2, particularly against p53-
null of mutant p53-expressing tumor cells. Additionally, LEM2 may open the way to new 
derivatives with improved pharmacological properties. 
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4. JL-1: A DUAL INHIBITOR OF THE P53 INTERACTION WITH 
MDM2/MDMX 
 
As referred above, MDM2 and MDMX, overexpressed in many human cancers, 
are two major endogenous inhibitors of wt p53 function (reviewed in [73]). Therefore, the 
development of small molecules that can abrogate this inhibitory effect of MDMs on p53 
represents an exciting strategy in anticancer drug discovery [71, 73]. In fact, several 
studies demonstrated that the treatment of wt p53-expressing tumor cells with inhibitors 
of the p53 interaction with MDM2/MDMX leads to a pronounced tumor growth-inhibitory 
effect, associated with increased p53 protein levels and with the up-regulation of its 
target genes (reviewed in [126]). To date, most of the research has been focused on the 
identification of inhibitors of the p53-MDM2 interaction. However, as previously referred, 
given its independent but also cooperative role with MDM2, MDMX has also shown to 
be essential for the fine regulation of p53 (reviewed in [172]). Moreover, despite the 
structural similarities of MDMX and MDM2, MDMX-overexpressing cancer cells showed 
to be highly resistant to MDM2-only inhibitors, which is a consequence of their inability 
to abolish the inhibitory effect of MDMX on p53 activity (reviewed in [71, 126]). These 
observations support that the simultaneous inhibition of MDM2 and MDMX, for a full p53 
reactivation in tumor cells, represents an appealing anticancer therapeutic strategy in 
cancer [73].  
To date, only four dual inhibitors of the p53 interaction with MDM2/MDMX have 
been described. In a previous work performed by our group, from the screening of a 
small library of phenylalaninol-derived oxazolopyrrolidone lactams using yeast-based 
assays, compound JL-1 was identified as a potential dual inhibitor of the p53-MDM2/X 
interactions. In these assays, human p53 induced a marked growth inhibition, which was 
abolished by human MDM2 and MDMX, and reestablished by inhibitors of these 
interactions (nutlin-3a for the p53-MDM2 interaction [154]; SJ-172550 for the p53-
MDMDX interaction [153]). Contrary to nultin-3a and SJ-172550, JL-1 was able to revert 
both the MDM2- and MDMX-inhibitory effects. 
With this work, it was intended to validate, in human tumor cells, the molecular 
mechanism of action of JL-1 as an inhibitor of the p53-MDM2/MDMX interactions. 
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4.1. RESULTS 
4.1.1. JL-1 ACTIVATES A P53-DEPENDENT PATHWAY IN WT P53-EXPRESSING 
HUMAN TUMOR CELLS  
To study the molecular mechanism of action of JL-1 as inhibitor of the p53-
MDM2/MDMX interactions, the effect of this compound was ascertained in HCT116 
p53+/+ and in HCT116 p53-/- cell lines. The GI50 values obtained for JL-1, after 48 h 
treatment, in p53+/+ and p53-/- HCT116 cells (Figure 15A), revealed that JL-1 has a p53-
dependent growth-inhibitory effect. In fact, the potency of JL-1 was significantly reduced 
when the p53 pathway was knocked out in HCT116 p53-/- cells.  
Further results showed that the growth-inhibitory effect of JL-1, at the GI50 (7 μM) 
and 2xGI50 (14 μM) concentrations, was associated with G0/G1-phase cell cycle arrest 
(Figure 15B), induction of apoptosis (Figure 15C), and PARP cleavage (Figure 15D), in 
HCT116 p53+/+, but not in HCT116 p53-/- cells.  
 
 
Figure 15 – JL-1 has in vitro antitumor activity and induces cell cycle arrest, apoptosis and 
PARP cleavage in p53+/+, but not in p53-/- HCT116 cells. (A) The GI50 concentration of JL-1 
was determined in p53+/+ and p53-/- HCT116 cells, after 48 h treatment, using the SRB assay; 
data are mean ± S.E.M. of four independent experiments; values significantly different from 
HCT116 p53+/+ cells are indicated (**p < 0.01). (B) JL-1-induced cell cycle arrest was determined 
after 24 h treatment. Cell cycle phases were analyzed by flow cytometry using PI staining; data 
are mean ± S.E.M. of three independent experiments; values significantly different from DMSO 
are indicated (*p < 0.05; **p < 0.01). (C) JL-1-induced apoptosis was determined after 24 h 
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treatment. Apoptosis was analyzed by flow cytometry using FITC-Annexin V and PI; data are 
mean ± S.E.M. of three independent experiments; values significantly different from DMSO are 
indicated (*p < 0.05; ***p < 0.001). (D) JL-1-induced PARP cleavage was analyzed by Western 
blot analysis after 24 h treatment; immunoblots are representative of three independent 
experiments; GAPDH was used as loading control. 
 
Additionally, by western blot analysis, it was shown that JL-1 led to p53 
stabilization and to the up-regulation of major p53 transcriptional targets, as revealed by 
the increased protein levels of MDM2, MDMX, Bax, Puma and p21 in p53+/+, but not in 
p53-/-, HCT 116 cells (Figure 16A). 
The ability of JL-1 to block the p53 interaction with MDM2 and MDMX was 
thereafter demonstrated using the co-IP assay, in HCT116 p53+/+ cells. At 7 and 14 μM, 
a visible decrease of the amount of MDM2 and MDMX co-immunoprecipitated with p53 
was observed (Figure 16B). Altogether, these results demonstrated that JL-1 was an 
activator of a p53 pathway in human tumor cells by blocking the p53-MDM2/X 
interactions. 
 
 
Figure 16 – JL-1 increases the expression levels of p53 and up-regulates p53 target genes 
by blocking the p53 interaction with MDM2/MDMX in p53+/+, but not in p53-/- HCT116 cells. 
(A) Western blot analysis was performed after 24 h treatment with 7 μM JL-1 or DMSO only; 
immunoblots are representative of three independent experiments; GAPDH was used as loading 
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control. (B) HCT116 p53+/+ cells were treated with 7 and 14 μM JL-1 or DMSO only for 24 h, and 
were immunoprecipitated with p53 or mouse immunoglobulin G (IgG) antibodies, followed by 
immunoblotting with MDM2, MDMX and p53 antibodies; whole cell lysate (IP); immunoblots are 
representative of three independent experiments; GAPDH was used as loading control. 
 
The effect of JL-1 was further tested in two other wt p53-expressing human tumor 
cell lines that overexpress one of the MDM proteins, namely in MDMX-overexpressing 
breast cancer MCF-7 cells and in MDM2-overexpressing osteosarcoma SJSA-1 cells. 
Although with higher GI50 values than the obtained in HCT116 p53+/+ cells (11.8 ± 0.7 for 
SJSA-1 and 13.3 ± 0.5 μM for MCF-7; Figure 17A), JL-1 also presented an evident 
growth-inhibitory effect in SJSA-1 and MCF-7 tumor cells, associated with the induction 
of cell cycle arrest (at G0/G1-phase in MCF-7 and at G0/G1- and S-phases in SJSA-1 
cells; Figure 17B), and apoptosis induction (Figure 17C), with PARP cleavage (Figure 
17D). Moreover, also in SJSA-1 and MCF-7 tumor cells, JL-1 led to p53 stabilization 
(Figure 17E and 17F, respectively), and to the up-regulation of several p53 transcription 
targets, as demonstrated by the increase of the protein levels MDM2 and Bax (the 
remaining targets are still under study) in SJSA-1 cells (Figure 17E), and of MDM2, 
MDMX, Bax, Puma and p21 in MCF-7 cells (Figure 17F). 
Altogether, this set of results demonstrated that JL-1 was also able to activate the 
p53 pathway in tumor cells mostly inhibited by MDM2 and MDMX. 
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Figure 17 – JL-1 induces growth inhibition associated with cell cycle arrest and apoptosis 
in MDM2- and MDMX-overexpressing tumor cells through activation of the p53 pathway. 
(A) The GI50 concentration of JL-1 was determined in SJSA-1 and MCF-7 cells, after 48 h 
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treatment, using the SRB assay; data are mean ± S.E.M. of four independent experiments. (B) 
JL-1-induced cell cycle arrest was determined after 24 h treatment. Cell cycle phases were 
analyzed by flow cytometry using PI staining; data are mean ± S.E.M. of three independent 
experiments; values significantly different from DMSO are indicated (*p < 0.05; **p < 0.01; ***p < 
0.001). (C) JL-1-induced apoptosis was determined after 24 h treatment. Apoptosis was analyzed 
by flow cytometry using FITC-Annexin V and PI; data are mean ± S.E.M. of three independent 
experiments; values significantly different from DMSO are indicated (**p < 0.01; ***p < 0.001). (D) 
JL-1-induced PARP cleavage was analyzed by Western blot analysis after 24 h treatment; 
immunoblots are representative of three independent experiments; GAPDH was used as loading 
control. (E) Western blot analysis was performed in SJSA-1 cells, after 24 h treatment with 11.8 
μM JL-1. (F) Western blot analysis was performed in MCF-7 cells, after 24 h treatment with 13.3 
μM JL-1. In (E) and (F), immunoblots are representative of three independent experiments; 
GAPDH was used as loading control.  
 
 
4.1.2. JL-1 HAS NO IN VITRO GENOTOXICITY  
The genotoxicity of JL-1 was cytogenetically tested by assessing its ability to 
induce MN in cultured peripheral lymphocytes of normal individuals. When compared to 
samples treated with DMSO only, 7, 14 and 21 μM JL-1 (corresponding to GI50, 2xGI50 
and 3xGI50 concentrations, respectively) did not increase the number of MN in 
lymphocytes (Figure 18). These results demonstrated that JL-1 has no apparent in vitro 
genotoxic activity. 
 
 
Figure 18 – JL-1 has no in vitro genotoxicity. The induction of micronucleus (MN) was tested 
in cultured peripheral lymphocytes of normal individuals, after 44 h treatment with JL-1, DMSO or 
cyclophosphamide, using cytokinesis-blocked micronucleus assay. The number of micronucleus 
per 1000 binucleated lymphocytes. Cells treated 1 μg/mL cyclophosphamide were used as 
positive control (C+); data are mean ± S.E.M. of three independent experiments; values 
significantly different from DMSO are indicated (**p < 0.01). 
 
 
 57 
 
4.1.3. JL-1 PREVENTS THE IN VITRO TUMOR CELL MIGRATION 
Cell migration is an essential process at many stages of embryonic development, 
for tissue repair and immune function. However, the deregulation of the cell motile 
behavior largely contributes to pathological processes, including tumor metastasis 
(reviewed in [173]). In fact, the acquired capability of tumor cells to invade and 
metastasize was established as a hallmark of cancer [2]. As such, the impact of JL-1 on 
the invasive ability of HCT116 p53+/+ cell lines was investigated by performing migration 
assays. In the Wound Healing Scratch assay, the images captured at the beginning and 
upon 20 and 24 h treatment showed that JL-1 inhibited the HCT116 p53+/+ cell migration, 
and the subsequent wound closure, when compared to cells treated with DMSO only 
(Figure 18). These results demonstrated that JL-1 is capable to inhibit the migration of 
human colon adenocarcinoma cells. 
 
 
Figure 19 – JL-1 prevents the migration of HCT116 p53+/+ cells. HCT116 p53+/+ confluent cells 
treated with 3 μM JL-1 (or DMSO only) were observed at different time points (0, 20 and 24 h) in 
the wound healing assay. 
 
 
4.1.3. JL-1 HAS POTENT IN VIVO ANTITUMOR ACTIVITY 
To evaluate the in vivo antitumor potential of JL-1, mice xenograft models 
carrying HCT116 p53+/+ tumor cells were used. The results revealed that four 
intraperitoneal administrations (twice a week) of 50 mg/kg JL-1 inhibited the growth of 
HCT116 p53+/+ tumors (Figure 19). The in vivo effect of JL-1 in HCT116 p53-/- tumor 
xenografts, to confirm its p53-dependent antitumor activity, is under analysis.  
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Figure 20 – JL-1 has in vivo antitumor activity. BALB/c nude mice carrying HCT116 p53+/+ 
xenografts were treated with 50 mg/kg JL-1 or vehicle (control); values significantly different from 
control mice are indicated (**p < 0.01, ***p < 0.001). 
 
 
4.2. DISCUSSION 
Several anticancer strategies have been devised to rectify a dysfunctional p53 
pathway, particularly due to the overexpression of MDM2 or MDMX. The simultaneous 
inhibition of the p53 interaction with MDM2 and MDMX has gained increasing attention 
as an anticancer therapeutic strategy, since it will conduct to a full p53 reactivation in wt 
p53-expressing tumor cells [71]. In this work, we identified a new dual inhibitor of the 
p53-MDM2/MDMX interactions, the enantiopure phenylalaninol-derived 
oxazolopyrrolidone lactam JL-1. Given the low number of this type of inhibitors, the 
identification of compound JL-1 may represent an important contribution to this field. 
In a previous work, a yeast targeted assay was used for the screening of inhibitors 
of the p53-MDM2/MDMX interactions from a small library of phenylalaninol-derived 
oxazolopyrrolidone lactams. From this analysis, the compound JL-1 was identified as a 
potential dual inhibitor of the p53-MDM2/MDMX interactions. In the present work, the 
molecular mechanism of action of JL-1 was validated both in vitro tumor cell lines and in 
vivo xenograft models. In fact, using human-derived isogenic tumor cell lines with and 
without p53, it was verified that the in vitro tumor growth inhibitory effect of JL-1 was 
highly dependent on p53, since a significant reduction of its potency was observed in the 
absence of the p53 pathway. Consistently with this, it was shown that the anti-
proliferative effect of JL-1 was associated with the induction of cell cycle arrest and 
apoptosis, in p53-expressing tumor cells, but not in p53-null tumor cells. Similarly, JL-1 
led to the stabilization of p53 protein levels, which is indicative of an inhibition of the 
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MDM2-mediated p53 degradation, and to the up-regulation of several p53 transcriptional 
targets in a p53-dependent manner. Finally, it was confirmed that JL-1 was able to block 
the p53-MDM2/MDMX interactions. Several evidences are therefore provided in this 
work supporting a dual inhibition of the p53-MDMs interactions by JL-1.  
 In this work, it was also shown a potent antitumor activity of JL-1 against wt-p53 
expressing human tumor cells with high levels of MDM2 and MDMX. Particularly, JL-1 
overcame the frequently reported resistance of MDMX-overexpressing tumor cells to 
MDM2-only inhibitors [71, 126]. This is of greatest importance since the overexpression 
of MDMs represent common mechanisms developed by tumor cells for disabling or 
attenuating specific p53 functions or the entire pathway [117]. Actually, in these cells, 
JL-1 also presented a growth-inhibitory effect, associated with the induction of cell cycle 
arrest and apoptosis, p53 stabilization, and up-regulation of p53 transcription targets. 
The earning ability to migrate and invade allows tumor cells to spread within the 
tissues and, consequently, to disseminate from the primary tumor to a distinct organ, fact 
that accompanies the tumor progression to more aggressive phenotypes. In fact, 
invasion and metastasis are the most frequent cause of death for cancer patients [174]. 
The loss of p53 function not only sustains tumor initiation and progression, but also 
allows tumor cells to more quickly acquire a metastatic phenotype [175]. In fact, p53 can 
regulate the transcription of several genes involved in the mechanisms underlying cell 
migration and invasion, such as cell motility and adhesion, signal transduction, inhibition 
of angiogenesis, extracellular matrix and cytoskeleton organization (reviewed in [175, 
176]). Based on this, it is expected that the restoration of the p53 function will lead to 
tumor regression and metastasis prevention. The results obtained in this work revealed 
that low doses of JL-1 prevented the migration of these cells. Beyond that, JL-1 showed 
to be a non-genotoxic compound. Finally, assays in xenograft mice models carrying wt 
p53-expressing tumor cells confirmed the in vivo antitumor activity of JL-1. Additional 
studies in xenograft mice models carrying p53-null tumor cells are underway in order to 
confirm the p53-dependent antitumor activity of JL-1. These results further support the 
promising antitumor properties of JL-1. 
 Although relevant findings about the mode of action of JL-1 were attained in this 
work, other studies must be performed in order to further elucidate this issue. In 
particular, it would be important to analyze the binding site of JL-1 (MDMs or p53), using 
biophysical assays.  
In conclusion, the results obtained in this work reveal the identification of a new 
selective activator of the p53 pathway through the dual inhibition of the p53-
MDM2/MDMX interactions. Besides this, evidences are provided by both in vitro and in 
vivo assays for the potential of JL-1 as anticancer agent.  
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5. GENERAL DISCUSSION AND FINAL REMARKS 
 
Diverse oncogenic events result in the activation of p53 family proteins and the 
induction of p53 family-dependent cell cycle arrest and apoptosis [95]. Therefore, the 
deregulation of the p53 family pathway plays a critical role in tumorigenesis [177]. As 
such, this family of proteins has been recognized as an appealing therapeutic target in 
cancer treatment. In fact, given its functional diversity in halting the propagation of cells 
carrying oncogenic lesions, as well as in blocking invasion and metastasis, the 
inactivation of the function of p53 family proteins is a very frequent event during tumor 
development, mainly through interaction with negative protein partners [108]. 
Nevertheless, many aspects of the molecular basis of these protein-protein interactions 
remain not completely clarified. Additionally, despite the amazing efforts that have been 
developed in order to find new and better molecular strategies to re-establish the p53 
function, small molecule modulators of the activity of p53 family proteins, particularly of 
p63 and p73, with improved pharmacological properties are highly required [177].  
In the present work, two new activators of the p53 and p73 pathways were 
identified. For that, the yeast cell system, having proved its importance earlier as highly 
effective first-line assay model [178], largely contributed for our findings. In fact, in 
previous works, it was shown that, as in human cells, also in yeast human MDM2 and 
MDMX were able to inhibit the p53 and p73 activity [152, 157]. These results revealed 
that yeast could be used as a model organism for a simplified cell-based screening assay 
to search for inhibitors of the interaction of p53 and p73 with MDMs [154, 157]. Herein, 
we provide a proof-of-concept for the effectiveness of this cell model as a screening tool 
with the identification of a new inhibitor of the p73-MDM2 interaction (the xanthone 
LEM2), and of a new dual inhibitor of the p53-MDM2/MDMX interactions (the 
phenylalaninol-derived oxazolopyrrolidone lactam derivative JL-1).  
For long, the p73 pathway has been considered an attractive target for anticancer 
drug development. In fact, several experimental and clinical evidences demonstrated 
that p73 can potentially emulate p53 functions in cancer cells, inducing apoptosis after 
DNA damage (reviewed in [58]). Several compounds that modulate the levels and activity 
of p73 by acting, either directly or indirectly, on its regulators were described (reviewed 
in [129]). However, to date, just the small molecule nutlin-3a was described as inhibitor 
of the p73-MDM2 interaction [131]. In this work, we identified a new inhibitor of this 
interaction, LEM2, which demonstrated a much higher in vitro antitumor potency than 
nutlin-3a in p53-null tumor cells. Although further work is required to confirm the 
molecular mechanism of LEM2, considerable therapeutic applications may be 
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anticipated for this compound, particularly against tumor cells with null or mutant p53. 
Additionally, LEM2 may open the way to a new class of activators of the p73 pathway 
with improved antitumor pharmacological properties. 
On the other hand, the dual inhibition of the p53-MDM2/X interactions is emerging 
as an exciting therapeutic approach, since it ensures the full activation of the p53 
functions [72]. Despite this, only a few number of this type of p53 activators were 
described to date. A great contribution is therefore provided by the present work to this 
area with the identification of JL-1 as a dual inhibitor of the p53 interaction with MDMs. 
This compound exhibited a p53-dependent in vitro growth inhibitory activity, and 
promising in vivo antitumor properties without apparent in vitro genotoxic activity. 
Additionally, it was capable of inhibiting the invasion of wt p53-harboring tumor cells, 
which reinforce its potential use as anticancer drug. Besides this, a new scaffold of dual 
inhibitors of p53-MDMs interaction was identified, which optimization may lead to 
derivatives with improved pharmacological properties as activators of the p53 pathway. 
The exploitation of synergic effects between these compounds (LEM2 and JL-1) 
and conventional chemotherapeutic drugs, to improve induced cell death, would further 
expand the therapeutic applicability of these compounds as anticancer agents. 
As a whole, with this project a relevant contribution was provided to the 
pharmacology of p53 family proteins, with the identification of promising small-molecule 
activators of the p53 and p73 pathway that can be further explored as potential 
anticancer agents. 
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